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The discovery of RNA interference and the increasing understanding of 
disease genetics have created a new class of potential therapeutics based on 
oligonucleotides. This therapeutic class includes antisense molecules, small 
interfering RNA (siRNA), and microRNA modulators such as antagomirs (antisense 
directed against microRNA) and microRNA mimics, all of which function by altering 
gene expression at the translational level. While these molecules have the promise 
of treating a host of diseases from neurological disorders to cancer, a major hurdle is 
their inability to enter cells on their own, where they may render therapeutic effect. 
Nanotechnology is the engineering of materials at the nanometer scale and has 
gained significant interest for nucleic acid delivery due to its biologically relevant 
length-scale and amenability to multifunctionality. While a number of nanoparticle 
vehicles have shown promise for oligonucleotide delivery, there remains a lack of 
understanding of how nanoparticle coating and size affect these delivery processes. 
This dissertation seeks to elucidate some of these factors by evaluating 
oligonucleotide delivery efficiencies of a panel of iron oxide nanoparticles with 
varying cationic coatings and sizes. A panel of uniformly-sized nanoparticles was 
prepared with surface coatings comprised of various amine groups representing high 
and low pKas. A separate panel of nanoparticles with sizes of 40, 80, 150, and 200 
nm but with the same cationic coating was also prepared.  
 Results indicated that both nanoparticle surface coating and nanoparticle 
hydrodynamic size affect transfection efficiency. Specific particle coatings and sizes 
were identified that gave superior performance. The intracellular fate of iron oxide 
 xviii 
nanoparticles was also tracked by electron microscopy and suggests that they 
function via the proton sponge effect. The research presented in this dissertation 














 Cancer remains one of the world’s most devastating diseases, with more than 
10 million new cases every year [1, 2]. In the United States, it is the second greatest 
killer, outpaced only by cardiovascular disease, and represents an annual economic 
burden of over $228 billion [3]. While the death of rate due to other common killers 
such as heart diseases, cerebrovascular diseases, pneumonia/influenza, has 
dropped precipitously over the past 50 years, there has been relatively little progress 
in battling cancer deaths. 
 This may be due in part to the enormous complexity of the disease. Cancer is 
caused by uncontrolled proliferation and the inappropriate survival of damaged cells, 
which results in tumor formation. Control of the processes of cell division, 
differentiation and death, however, is coordinated by a large number of regulatory 
factors, damage to whose genes (also known as oncogenes and tumor suppressor 
genes) is selected for in cancer [4]. This genetic damage is by no means 
homogeneous; it can involve many different mutations on many different genes. In 
addition, disease results not from any single mutation but from the gradual 
accumulation of genetic damage. The somatic acquisition of large numbers of 
mutations coupled with the variability in the host’s genetic constitution produces a 
disease of enormous heterogeneity and complexity—so much so that it may not be 
an exaggeration to suggest that 100 breast cancer patients represent 100 distinct 
diseases [5]. 
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 This complex genetic nature of cancer suggests that traditional methods of 
characterizing tumors by gross visual information—such as size of tumor, degree of 
spread, general histological characterization, along with limited biochemical 
assays—and traditional methods of treatment—such as broad exposure to cytotoxic 
chemotherapeutics—is inadequate. The success of new methods that dissect cancer 
heterogeneity by assaying a panel of genetic biomarkers for personalized and more 
accurate disease diagnosis/prognosis, and the success of new biologic drugs that 
treat cancer with molecular specificity, underscore the importance of 
genetomolecular analysis and intervention [6-12].  
 Nucleic acids represent important diagnostic and therapeutic biomolecular 
targets in cancer. Studies have shown that cancer-related cell-free DNA can be 
detected in blood and other biological fluids as a noninvasive method for cancer 
diagnosis and profiling [13, 14]. RNA-based profiling has also shown promise in 
classifying cancers into clinically relevant subtypes [15, 16]. In the realm of 
therapeutics, siRNA and other oligonucleotide drugs seek to treat cancer by 
interacting directly with the genes responsible for disease progression [17, 18].  
 The potential use of nucleic acids for cancer applications is still limited by 
issues such as sensitivity, specificity, and effective delivery methods. 
Nanotechnology, which involves the engineering of materials at the nanoscale, 
promises to overcome these limitations. The size regime of nanotechnology is on the 
same scale as biologically relevant molecules and structures, enabling the design of 
materials that interact specifically with biology at a fundamental level. Unique 
properties of materials at the nanoscale that are not present in their bulk phases also 
present opportunities for improving sensitivity and specificity of biomedical assays 
and interventions [19].  
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1.2 Dissertation Organization 
 This dissertation will explore the use of two types of nanoparticles—
semiconductor quantum dots and iron oxide nanoparticles—for nucleic acid-based 
assays. These technologies will be used for two specific applications: DNA detection 
in solution, which may be extended for noninvasive genetic analysis of biological 
fluids for cancer diagnosis and prognosis, and intracellular oligonucleotide delivery, 
which may yield insights in the use of nanotechnology for the clinical application of 
oligonucleotide drugs. 
 This dissertation has been organized into 7 chapters. This chapter has given 
a broad overview of cancer as a heterogeneous disease and presents some 
motivation for the development of new methods for the diagnosis and treatment of 
cancer.  
 Chapter 2 will provide some background on quantum dots and iron oxide 
nanoparticles, the two types of nanoparticles that will be explored in this dissertation 
for use in cancer applications. We will then describe the biological applications for 
which these technologies will be used: DNA detection and oligonucleotide delivery. 
For DNA detection, circulating DNA will be discussed as a target for detection. Its 
potential utility in the management of cancer throughout the treatment process will 
be developed. For oligonucleotide delivery, we will describe the tremendous promise 
oligonucleotide drugs present for the treatment of cancer as well as many other 
diseases, but also the limitation that currently exists in their widespread application: 
the need for a delivery vehicle.  
 Chapter 3 describes a method we have developed for detecting DNA 
sequences in an optical assay involving single magnetic microbeads coated with 
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quantum dots as a fluorescent reporter. The superior optical properties exhibited by 
QDs combined with the advantage of using magnetic beads for magnetic enrichment 
and isolation enable sensitive target detection.  
 Chapters 4, 5, and 6 will describe our investigation of iron oxide nanoparticles 
for delivery of antagomir, one type of oligonucleotide drug. We prepare a panel of 12 
SPIONs all containing different amine coatings in Chapter 4. We describe our 
reaction procedure and characterize the prepared particles as well as their DNA 
binding properties.  
 In Chapter 5, we will use the 12 particles prepared in Chapter 4 to deliver 
antagomir to antagonize a cancer-related microRNA. Transfection efficiencies for the 
12 particles are reported and we identify one that exhibits superior delivery. We also 
use one of these particles to study the intracellular delivery process through TEM 
and fluorescent imaging. 
 Chapter 6 evaluates how nanoparticle size affects intracellular antagomir 
transfection. We prepare SPIONs with diameters of 40, 80, 150, and 200nm and use 
them to transfect cells. Transfection efficiencies are reported as well as supporting 
data from TEM and fluorescence imaging experiments.  
 We close in Chapter 7 with conclusions from our studies and propose future 
directions based on these findings.  
 Appendix A will present data from the use of quantum dots for antagomir 
transfection, with may yield some insights when combined with the data presented in 
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 The promise of nanotechnology for both cancer detection and therapy is quite 
compelling. The length scale of nanoparticles is on the same order as many 
biological molecules such as DNA and large proteins, making them ideally suited to 
probe individual molecules and interact with biological processes on a fundamental 
level [1, 2]. Moreover, nanoparticles often exhibit unique properties that are not 
available in their bulk materials [2, 3]. These unique properties can make 
nanoparticles particularly advantageous for certain applications. Both quantum dots 
and iron oxide nanoparticles have already found important uses in imaging, 
diagnosis, and therapy. In this chapter, we provide a brief overview of QDs and iron 
oxide nanoparticles. We then introduce the fields of nucleic acid detection and 
oligonucleotide therapies, two areas where nanotechnology can be harnessed to 
improve human health. 
 
 
2.1 Semiconductor Quantum Dots 
 
 Quantum dots (QDs) are semiconducting nanoparticles with unique optical 
properties which differ from their bulk material properties. They can be synthesized 
from various types of semiconductor material such as II-VI (e.g. CdS, CdSe), III-V 
(e.g. InP, InAs), or IV-VI (e.g. PbSe) [4]. CdSe QDs capped with a thin layer of ZnS 
are the most frequently used, however, for biological experiments as the band-gap 
energy of CdSe spans the visible region (400-800nm) of the electromagnetic 
spectrum [5-7]. Due to quantum confinement effects at the nanoscale, QDs may be 
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tuned by size or composition to emit light at varying wavelengths. They are very 
bright and photostable, being about 10-100 times brighter and 100-1000 times more 
photostable in comparison to organic dyes or fluorescent proteins [8]. Their broad, 
continuous absorption spectra and narrow emission spectra also allow for multiple 
colors to be simultaneously excited using a single excitation source (Figure 2.1). 
These properties enable QDs to be used for sensitive and quantitative multiplexed 
detection and make them ideal candidates for biomolecular imaging. 
 Indeed, QDs have been used for a variety of biological applications including 
immunohistochemistry, live cell imaging, drug delivery, and other bioanalytical 
assays requiring fluorescence [9-15]. Highlighting the unique features of these 
particles, Fountaine et al demonstrated the use of up to five different colored QDs for 
the simultaneous staining and imaging of five clinically relevant protein targets in 
cancer tissue [11]. The superior brightness and photostability of QDs also enabled 
Dahan et al to image the diffusion dynamics of single glycine receptors on neuronal 
membranes of living cells tagged by single quantum dots [16]. 
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Figure 2.1: Spectral properties of quantum dots. Panel on left illustrates the size-
dependent nature of QD fluorescence. Panel on right demonstrates superior optical 
properties of QDs relative to chemical dyes [17]. Note that the emission peak is more 
narrow and symmetric for the QD spectrum, and the absorption band extends far into the 
ultraviolet region. The size differences of FITC and QD are also shown [18]. 
 
 
2.2 Iron Oxide Nanoparticles 
 Iron oxide nanoparticles, also called superparamagnetic iron oxide 
nanoparticles (SPIONs) are another class of nanoparticles that offer attractive 
possibilities for biomedicine due to their unique properties. First, they are relatively 
nontoxic and have already been FDA approved for in vivo imaging as a magnetic 
resonance imaging (MRI) contrast agent [19]. Second, they can be synthesized over 
a relatively large size range, from a few nanometers up to tens of nanometers [19, 
20]. Larger particles can be synthesized as clusters of smaller particles. Third, IO 
nanoparticles are paramagnetic and can thus be manipulated by an external 
magnetic field. This property means that they are magnetic only in the presence of 
an external field. Once the external magnetic field is removed, the nanoparticles lose 
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their magnetism. This enables a variety of applications such as the enrichment and 
purification of molecules or cells or even magnetically assisted drug delivery where 
an external magnetic field is placed outside the body near the site of intended 
particle accumulation after drug-loaded IO nanoparticles are injected systemically 
[21-23]. Fourth, IO nanoparticles can used as hyperthermia agents to kill tumors by 
heat. This can occur by the transfer of energy from an exciting time-varying magnetic 
field to the nanoparticle[24, 25].  
 Besides these applications of magnetic separation, drug delivery, and 
hyperthermia treatments, a major use of IO nanoparticles is as a magnetic 
resonance imaging (MRI) contrast agent. MRI relies on the counterbalance between 
the exceedingly small magnetic moment on a proton and the exceedingly large 
number of protons present in biological tissue, which leads to a measurable effect in 
the presence of large magnetic fields [19, 26, 27]. This signal can be captured by 
applying a time-varying magnetic field in a plane perpendicular to the first field, 
causing a coherent response from the net magnetic moment of the protons. Once 
this second oscillating field is turned off, the relaxation of the coherent response is 
measured. Due to their superparamagnetism, Iron oxide nanoparticles can be used 
to enhance MRI contrast by reducing this relaxation time, improving diagnostic 
sensitivity and specificity [28, 29]. For cancer imaging, they have been used to assist 
the identification of malignant lymph nodes, liver tumors, and brain tumors [19, 30-
32]. 
 
2.3 DNA and RNA Detection 
 
 DNA and RNA are both important molecules used for detection and diagnosis 
of diseases such as cancer. Cancer is a genetic disease and is characterized by 
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aberrations that can give rise to genetic mutations, microsatellite alterations, 
chromosomal inversion, deletion, or recombination and promoter hypermethylation 
[33]. These can give rise at the RNA level to mutated genetic transcripts or altered 
expression of normal genes [34]. Both DNA and RNA, therefore, present themselves 
as promising targets for cancer detection, diagnosis/prognosis, therapy, and 
surveillance of therapeutic response.  
  It is known that when cancer is discovered early, patients live longer, require 
less extensive treatment, and, in general, fare much better than patients with more 
advanced cancer [35, 36]. Moreover, it has been found that nucleic acids in the 
plasma, serum, and other biological fluids of cancer patients contain a fraction that is 
of tumor origin [33, 37]. These so-called circulating nucleic acids (CNAs) present a 
promising opportunity to detect cancer through an in vitro blood assay. Such a test 
could have profound benefits not only for early detection of cancer but also, after 
detection, for disease prognosis and monitoring of therapeutic efficacy as CNAs 
have been found to have value for these applications as well [38-41]. Figure 2.2 
illustrates how methods to detect DNA can be utilized throughout disease 
progression to assess risk of disease development by inherited genetic 
predispositions, to detect disease at its earliest stages, to diagnose disease, to 






Figure 2.2: Appropriate biomarkers may be able to define risks and identify the 
early stages of tumor development, assist in tumor detection and diagnosis, verify 
stratification of patients for treatment, predict outcomes of the disease, and help 
in surveillance for disease recurrence [35]. 
  
 
2.4 Oligonucleotide Therapies 
 
 Oligonucleotide therapies such as antisense, siRNA, and microRNA have 
gained enormous attention in the past two decades as potential means to treat a 
wide host of intractable diseases. As many diseases such as genetic disorders, 
degenerative diseases, infections, and malignancies have a genetic basis, the 
promise of these molecules lies in their ability to modulate disease genetics, though 
at the RNA level. Discovered in the late 1970s, antisense molecules are generally 
single-stranded DNA fragments of 8-50 nucleotides in length that bind to messenger 
RNA through Watson-Crick base pairing [42]. The two molecules form a DNA-RNA 
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heteroduplex which is recognized by RNase H, which then cleaves the RNA strand 
and releases the intact DNA strand. While mRNA degradation is the major mode of 
action, some antisense oligonucleotides have been shown to effect translational 
arrest or alternative splicing [43]. The early discovery of antisense has led to its 
being the best understood class of therapeutic oligonucleotide, accounting for the 
majority of drugs in development. 
 Discovered in the late 1990s, siRNA are chemically synthesized double-
stranded RNA sequences of 19-23 base pairs with a two nucleotide overhang on the 
5’-phosphorylated end and an unphosphorylated 3’-end [44-46]. They knock down 
gene expression through the RNA interference mechanism. Briefly, the double-
stranded siRNA is loaded into a protein-RNA complex known as the RNA induced 
silencing complex (RISC). RISC separates the two strands of the siRNA, discards 
the sense strand, and directs the antisense strand to bind to a target mRNA. 
Knockdown is achieved by mRNA cleavage by the enzyme Argonaute 2 [47, 48]. 
 MicroRNA are similar to siRNA in that they are also double-stranded 
sequences of RNA about 20-22 base pairs in length that regulate gene expression 
through the RNAi pathway [49]. Like siRNA, miRNA are loaded onto the RISC 
complex, brought to a complementary mRNA, and signal that mRNA’s cleavage or 
translational arrest. miRNA, however, are also distinct in a number of ways. First, 
miRNA are endogenous agents in cellular regulation whereas siRNA are chemically 
synthesized. The former are transcribed as parts of longer transcripts known as 
primary miRNA (pri-miRNA), processed into shorter segments (pre-miRNA) by the 
enzyme Drosha, then processed again by Dicer to remove a stem-loop to become 
the mature miRNA (Figure 2.3) [50]. Second, evidence exists that some miRNA are 
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responsible for regulating several mRNA transcripts whereas most siRNA are 




Figure 2.3: Developmental pathway of miRNA [50]. 
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The therapeutic potential of miRNAs exists in the fact that they have been 
found to be fundamental gene regulators controlling proliferation, differentiation, and 
apoptosis during development and have been implicated in a large host of diseases 
including cancer [49, 52-56]. As cancer gene regulators, miRNAs function as both 
oncogenes and tumor supressors. Antisense molecules may thus be delivered to 
inhibit overexpressed miRNA (e.g. oncogenes) and miRNA mimics may be delivered 
to increase miRNA that are weakly expressed (e.g. tumor suppressors). For the sake 
of clarity, antisense molecules directed towards miRNA will hereafter be referred to 
as antagomirs [57]. 
 
 
2.5 Oligonucleotide Delivery 
 
 While oligonucleotides hold great therapeutic promise, a major issue is 
delivery as they are prone to degradation by serum nucleases, may stimulate innate 
immune response, and—owing to the negative charge of their phosphate backbone 
and hydrophilicity—are unable to traverse the  anionic cell membrane [4, 58-64]. 
Viral vectors, benefitting from evolutionary optimization, have a high transfection 
efficiency; however, fundamental problems related to toxicity, immunogenicity, and 
scale-up procedures have encouraged the investigation of alternative nonviral 
approaches such as cationic lipids, dendrimers, polymers, and other nanoparticles 
[65]. These nonviral vectors exhibit relatively inferior, though still significant, 
efficiency and have improved toxicity profiles. Cationic polymers, in particular, are a 
promising nonviral approach due to their ability to be extensively modified and to 
other advantageous features for pharmaceutical products including reproducibility of 
preparation and stability for long-term storage [66].   
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In order to efficiently deliver oligonucleotides, polymer vectors must achieve a 
number of important steps (Figure 2.4). First, they must bind to, or complex with, the 
oligonucleotide. For the case of cationic polymers, this typically occurs through 
electrostatic interaction. Second, the polymer-oligonucleotide complex must enter 
the cell. This can occur through either targeted or nontargeted means. For targeted 
entry, the polymer is conjugated to a ligand or other targeting agent that will bind to 
cell-surface receptors to effect receptor-mediated endocytosis. For nontargeted 
entry, cellular internalization still occurs through endocytosis although the exact 
mechanism is still not understood [67, 68]. Generally, untargeted polymer complexes 
still maintain a slight positive charge even upon binding of the DNA/RNA, causing it 
to associate with the anionic cell membrane, which should assist in internalization. 
Finally, the oligonucleotide must be able to escape from the endosome. Endosomal 
escape can occur in several ways including incorporation of the lysosomotropic 
agent chloroquine or membrane-destabilizing peptides such as the N-terminal 
peptides of Rhinovirus VP-1 [69, 70]. Alternatively, incorporation of amine groups 
may exploit the so-called “proton sponge effect” [71]. Briefly, initial internalization is 
followed by sequential intracellular trafficking into a variety of low pH endomembrane 
compartments, including endosomes and lysosomes [72]. As the endosomal pH 
lowers (pH 5.0-6.2) amines with low pKa values start to be protonated and thus 
buffer the acidic environment [73, 74]. To counter this buffering capacity, cells pump 
H+ to acidify the endosomal compartment. This, however, is accompanied by 





Figure 2.4: Mechanism of nanoparticle delivery of oligonucleotides. Adapted from 
Anderson et al [76]. 
 
 
 As a next step from pure cationic polymer vectors, several groups have 
developed cationic polymer-coated inorganic nanoparticles as multifunctional 
delivery vehicles. There are several advantages to this approach. First, because 
inorganic nanoparticles are typically rigid with a well-defined structure, they afford 
the ability to engineer delivery vehicles with carefully controlled sizes and shapes to 
optimize biological interaction [77-80]. Second, they can serve as a scaffold upon 
which multiple functionalities, such as drugs, targeting agents, cationic amines, and 
pH buffering groups can be attached. Third, the inorganic nanoparticles themselves 
may exhibit unique properties that may be exploited to improve therapeutic 
performance. For instance, semiconductor nanoparticles (i.e. quantum dots) exhibit 
fluorescent properties that may be used for simultaneous drug delivery and optical 
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imaging for monitoring of delivery [81, 82]. Mesoporous silica nanoparticles can be 
used for simultaneous small-molecule drug and nucleic acid delivery by interiorly 
loading the particles with nanovalves and drugs for on-demand drug release while 
loading the surface of the particles with cationic polymer and nucleic acids [83]. Iron 
oxide nanoparticles exhibit superparamagnetic, hyperthermia and magnetic 
resonance properties that confer use for magnetically-assisted drug delivery, thermal 
ablation therapy, and magnetic resonance imaging [84]. Gold nanoparticles exhibit 
optical and photothermal properties that can be used for monitoring of delivery as 
well as for photothermal therapy [85].  
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CANCER-ASSOCIATED DNA DETECTION BY QUANTUM DOT 
NANOCRYSTALS ON SINGLE MAGNETIC MICROBEADS 
 
3.1 Introduction 
  Cancer is the second greatest cause of death in the United States after heart 
disease [1]. In the fight against this disease, an important conclusion has been 
made: Early detection of cancer is critical for successful intervention and survival [2]. 
According to data reported by the NCI Surveillance Epidemiology and End Results 
(SEER) Program, patients having noticeable tumors have high five-year survival 
rates (91.1% for skin melanoma and 88.6% for breast cancer) whereas those having 
tumors of internal organs have low five-year survival rates (10.8% for liver & 
intrahepatic bile duct and 5% for pancreas). Such a high disparity in outcomes 
between cancer in observable sites and in internal organs indicates how frequently 
tumor detection depends on either direct inspection (e.g. skin melanoma) or 
enhanced imaging (e.g. mammography for breast cancer) and highlights the need 
for improved methods to detect cancer at its earliest stages [3].  
 The discovery of tumor-related DNA in blood and other biological fluids 
presents a potential assay to noninvasively detect cancer at early stages [4, 5]. Leon 
et al demonstrated that cancer patients had much higher circulating DNA 
concentrations than those suffering from non-malignant diseases. Moreover, in some 
cases, the levels of circulating DNA would decrease after successful anticancer 
therapy [6, 7]. Since this discovery, further studies have been performed 
demonstrating that cancer-related genetic mutations (such as N-ras in 
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myelodysplastic syndrome and K-ras in pancreatic and colorectal cancer) [8-10], 
DNA rearrangements [4], and microsatellite alterations [11, 12], could all be detected 
in the serum of patients. 
 Magnetic microbead (MMB) technology is a promising technology for 
detecting molecules such as circulating nucleic acids (CNA). They are usually 
embedded with superparamagnetic iron oxides such that they can be mixed readily 
with biological samples and only exhibit magnetic properties—and thus be used for 
sample purification/collection—in the presence of an external magnetic field. They 
have already been used in a number of studies for purifying and enriching specific 
proteins and nucleic acid sequences in solution with high specificity [13-18].  
 Most MMB studies involving the capture and analysis of biological targets, 
however, have relied upon traditional fluorescent dyes, which suffer from relatively 
poor photostability and photobrightness. Fluorescent nanoparticles such as quantum 
dots (QDs), however, have improved brightness and photostability that enable their 
use in ultrasensitive detection formats [19-22]. Indeed, QDs are so bright that 
individual particles can be observed through a fluorescent microscope [23].  
 We present here a bead-based sandwich assay wherein free cancer-related 
DNA in solution is collected and enriched by MMBs. QDs are then used as a reporter 
dye to detect captured DNA on the MMBs. Standard fluorescence microscopy, 
spectroscopy, and image analysis are used to analyze and quantify single beads 
and determine target concentration based on total fluorescence intensity. The 
advantage of this method is that it combines the ability of MMBs to enrich low 
concentration targets with the superior optical properties of QDs to enable sensitive 





 Streptavidin-coated 655 nm emitting quantum dots were purchased from 
Invitrogen (Foster City, CA). Streptavidin-coated magnetic microbeads (~1um in 
diameter) were purchased from Bangs Labs. DNA probes were purchased from IDT 
(Coralville, IA) and sequences were as follows: Probe 1 5’- 
GTTCAGTTTCTCGGGAAAAAAAAAAA-biotin triethylene glycol -3’; Probe 2 5’ - 
biotin triethylene glycol-AAAAAAAAAACTCCTCCAGCTCCT – 3’; BCAR3 Target 
Probe: 5’- CCCGAGAAACTGAAGAAGGAGCTGGAGGA - 3’ 
 
QD and Magnetic Bead Conjugation 
 To determine the optimal amount of DNA probe that should be conjugated to 
the quantum dots, 2 ul of 1 uM streptavidin QDs with emission maxima of 655 nm 
were incubated with varying amounts of Probe 1 for 2 hours at room temperature. As 
the manufacturer estimates ~16 available biotin-binding sites per QD, an excess (10 
ul of 200 ng/ml) of free biotin was then added to each reaction mixture to saturate 
any unoccupied biotin-binding sites on the QDs. Electrophoresis was then performed 
to verify successful conjugation of probe to QD using a 0.8% agarose/0.1% Tween-
20 in 1X TBE buffer. Gels were fun for 20 minutes at 105 V. In subsequent 
experiments 1:1.5 molar ratio of QD:Probe 1 was used. 
 MMBs were conjugated to Probe 2 by incubating 510,000 beads with a 20-
fold excess of biotinylated Probe 2 to biotin-binding site per MMB in 0.1M borate 
buffer (pH 8) in a 1.5 ml Eppendorf Tube. The mixture was incubated for 2 hours 
with rotation on a Labquake rotator (Barnstead/Thermolyne). Beads were then pulled 
out of solution by placing on a 1.5 Tesla NdFeB permanent magnet (MCE Products, 
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Torrance, CA) and washed 3 times in 0.1 M borate buffer. An excess of free 
streptavidin was the added to prevent any unbound Probe 2 from being captured by 
QDs in subsequent steps. Beads were applied to a magnet and washed an 
additional 3 times in 0.1 M borate buffer. 
 
DNA Detection 
 For DNA detection, an appropriate amount of BCAR3 target was added to a 
tube containing 1 ml of hybridization buffer (2.82 ul salmon sperm DNA (Invitrogen), 
2.56 ul E.Coli tRNA (Roche), 20 ul 50X Denhardt’s in 1XSSC/0.2%BSA/0.1%NaN3). 
This was allowed to prehybridize for 2 hours at room temperature. All of the Probe 1-
conjugated QDs and 100,000 beads of the Probe 2-conjugated MMBs were then 
added to the reaction mixture and allowed to hybridize overnight on a Labquake 
rotator (Barnstead/Thermolyne). Particles were then washed once for 10 min in 
1XSSC/0.2%BSA/0.1%NaN3, twice for 30 min in 0.5XSSC/0.2%BSA/0.1%NaN3, and 
finally 3 times briefly in 0.1M borate buffer. 
 
Data Acquisition and Analysis 
 
 The bead suspension was volume reduced to 10-20 ul by magnetic 
separation and placed between two glass coverslips (no. 1 coverglass, Corning Inc., 
Corning, NY) for imaging on an Olympus IX-71 microscope (Center Valley, PA) that 
was equipped with a mercury lamp for excitation, a Nikon D70 color digital camera, 
and a 100X objective (NA 1.25, oil). True color fluorescence images were obtained 
by using 488-nm exicitation and a long pass filter (505nm, Chroma Technology 
Corp., Brattleboro, VT). The fluorescence spectra of pure QDs were recorded by 
using a standard fluorometer (FluoMax; Jobin Yvon, Edison, NJ). Fluorescence 
spectra of single beads containing QDs were recorded by using a spectrophotometer 
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(SpectraPro 150, Roper Scientific, Trenton, NJ) attached to the side port of the 
microscope. All images were analyzed by using NIH Image J software [24].  
 
3.3 Results and Discussion 
The procedure for the DNA detection assay is shown in Figure 3.1. In this 
procedure, 655nm emission quantum dots and magnetic microbeads are conjugated 
to oligononucleotide Probes 1 and 2, respectively, that are designed to sandwich a 
biologically relevant target sequence, a 29-mer portion of BCAR3. BCAR3 (Breast 
Cancer Antiestrogen Resistance-3), is a member of the novel Src homology 2 (SH2)-
containing protein family that may promote an epithelial-mesenchymal transition in 
breast cancer cells [25-27]. It was first identified in a screen for genes whose 
overexpression conferred resistance to antiestrogens and may thus aid in 
therapeutic strategy decisions for breast cancer patients [28, 29]. Hybridization of 
this target sequence with the two oligonucleotide probes causes the QDs to 
surround the MMBs. After magnetic separation and enrichment, these complexes 
can then be imaged using a fluorescence microscope and the QD fluorescence 
emission on each MMB quantified. The fluorescence measurements are averaged 
over several beads and the amount of target oligonucleotide in solution can be 




Figure 3.1: Schematic illustration of sandwich assay using magnetic microbeads 
and quantum dots to detect BCAR3 DNA fragment. 
Probe Conjugation 
 
 QD-Probe 1 conjugation must be controlled to ensure proper binding of the 
particles. Having too many probes conjugated per QD can give rise to several 
undesired effects. First, it can cause aggregation of QD/beads with QDs crosslinking 
multiple microbeads, making difficult the ability to accurately measure fluorescence 
from single beads. Second, there is the potential for multiple target DNA to bind to a 
single QD. This could lead to some target DNA not being detected either because 
steric issues would prevent them from binding to an MMB or because multiple target 
DNA bridge the same QD-MMB pair. Ideally, each QD would have one Probe 1 
MMB QD Target DNA 
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attached such that each QD docked onto an MMB would represent a single target 
molecule in solution. 
 To control the amount of Probe 1 conjugated per QD particle, a gel migration 
assay was performed. Streptavidin-conjugated QDs were incubated with biotin-
labeled Probe 1 in 5:1, 2:1, 1:1, 1:1.5, 1:2, 1:5, and 1:10 QD:Probe 1 molar ratios 
and the migration patterns of the conjugated complexes were evaluated by gel 
electrophoresis. As QDs are conjugated to Probe 1, the negative charge from the 
DNA should cause the particles to migrate further down the gel towards the cathode. 
Figure 3.2 shows that starting with a 5:1 QD:Probe 1 ratio, most of the QDs do not 
exhibit any enhanced migration relative to the lane containing QDs alone. There is a 
faint smear further down the lane, however, which corresponds to some of the 
particles having bound some DNA. As the amount of Probe 1 incubated per QD is 
increased, the band corresponding to unconjugated QD fades and the QDs migrate 
further and further down the gel. 
 Interestingly, a faint discrete band (see arrow) appears in the 5:1 lane just 
below the band corresponding to unconjugated QDs that increases in intensity as 
the amount of DNA probe is increased, reaching a maximum at a 1:1.5 QD:Probe 1 
ratio. Seeing as this band appears at a 5:1 ratio, it may correspond to QDs with only 
one Probe 1 attached, consistent with other reports of discrete electrophoresis 
bands arising from discrete numbers of oligonucleotides conjugated onto 
nanoparticles [30, 31]. We thus decided to conjugate QDs at a 1:1.5 QD:Probe 1 




Figure 3.2: Gel mobility assay demonstrating QD-Probe1 conjugation. Streptavidin-
conjugated QDs were incubated with biotin-Probe1 at various ratios. Arrow points out 
faint discrete band that may correspond to QDs conjugated to a single Probe1. Ratios 




 Because quantum dots and oligonucleotides can both exhibit nonspecific 
binding and hybridization, for target detection experiments we also wanted to 
evaluate several conditions to optimize signal to noise ratio. We evaluated target 
detection under conditions of differing temperatures as well as blocking buffers, 
while keeping all other variables constant. For temperature, we performed the 
sandwich assay at both room temperature as well as at a slightly elevated 
temperature of 30C, which should decrease some nonspecific hybridization of DNA 
(e.g. between probe 1 and probe 2 directly without target DNA bridging the two). We 
also performed a blocking step on the beads whereby we exposed the MMBs to a 
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mixture of blocking agents prior to adding the target oligonucleotide or Probe 1-
conjugated QDs. For blocking buffer, we evaluated both 0.2% BSA mixtures 
containing or not containing Denhardt’s Solution, which contains Ficoll 400 and 
polyvinilpyrolidone to minimize nonspecific interaction of oligonucleotides with 
substrates and is frequently used in in situ hybridization experiments. Figure 3.3 
shows our results for this optimization study. There was a statistically significant 
improvement in the signal-to-noise ratio (SNR) when the temperature was increased 
to 30C versus room temperature. No statistically significant difference was observed, 
however, with the addition of Denhardt’s Solution. Interestingly the increase in SNR 
at 30C was accompanied by an increase in overall signal. This indicates that the 
slight increase in temperature decreased nonspecific binding of oligonucleotide pairs 






 RT 30C 
Denhardt's 
Solution - + - + 
SNR 53.6 ± 10.4 49.7 ± 10.1 103.9 ± 27.1 121.2 ± 36.0 
 
Figure 3.3: Signal-to-noise under varying temperature and incubation buffer 
conditions. SNR was improved by performing sandwich assay at 30C versus RT. 





 Having optimized the SNR for the bead assay, we performed the experiment 
on a range of target DNA concentrations (20 fM to 2 pM) to investigate the sensitivity 
of the assay. Figure 3.4 shows that a decrease in target oligonucleotide 
concentration is accompanied by a decrease in QD fluorescence signal. This 
decrease is also observable through fluorescence images of representative beads. It 
should be noted that even with blocking and washing, beads incubated with QD 
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alone and no target oligonucleotide had a non-zero signal. In fact a faint QD signal 
could be detected on the bead surface in fluorescence images of this sample (Figure 
3.4C). This became the limiting factor for detection sensitivity as we were able to 
obtain a statistically significant signal for concentrations as low as 200 fM. While 
there was an observable difference in signal for the sample containing 20 fM target 
versus that containing no target, this difference was not statistically significant (p-


























Figure 3.4: Single MMB hybridization assay for BRCA1 detection using QDs. (A) 
Representative image showing uniform coating of QDs on MMBs. (B) and (C) Results of 
assay when incubated with varying target DNA concentrations. 
 
 
0 20 fM 200 fM 2 pM 20 pM p < 0.11 p < 0.016 p << 0.001 p << 0.001 
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 A 200 fM concentration of target DNA represents approximately 100 target 
DNA, and hence ideally 100 QDs per MMB. Of course, the actual number of QDs 
tethered to each bead by a target DNA may not be 100 for the 200 fM target 
concentration case, potentially due to a variety of reasons. First, there will be a 
population of QDs that are conjugated to more than one Probe 1. QD-Probe 1 
conjugation was performed at a 1:1.5 molar ratio. Gel electrophoresis experiments 
have demonstrated that while a discrete band appears indicating what may be a 1:1 
conjugation ratio, a smear still exists, indicating a heterogeneous population. QDs 
with more than one Probe 1 attached may either tether to the magnetic beads 
through more than one site or may otherwise simply sequester target DNA that will 
be unable to be bound to beads due to steric or other influences. Second, there is 
the possibility that after conjugation and purification, some of the conjugated probes 
may detach from either the QD or MMB. Free oligonucleotide probes will hybridize to 
target oligos and compete with QD- or MMB-bound probes. Lastly, as the 
concentrations of probes and target DNA are relatively low, there is the possibility 
that hybridization just does not occur as not all molecules are able to find each other. 
This could be resolved by increasing concentrations of Probe 1-bound QDs or of 
Probe 2-bound MMBs, but higher concentrations could also lead to increased 
nonspecific binding. 
 We have demonstrated in this study a method to semi-quantitatively detect a 
cancer-associated DNA sequence in solution. We were able to achieve detection 
sensitivity to as low as 200 fM. Below this level, signal did not differ significantly from 
that observed from nonspecific interactions. The detection limit of this method may 
be improved by using fewer MMBs or by further optimizing the assay to lower 
nonspecific interactions. This assay has potential applications in disease diagnosis 
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and monitoring of therapeutic response as oligonucleotide biomarkers as detected in 
bodily fluids have demonstrated such clinical value [32, 33].  
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SYNTHESIS AND CHARACTERIZATION OF AMINE-
FUNCTIONALIZED IRON OXIDE NANOPARTICLES  
 
4.1 Introduction 
 With the completion of the human genome project and the increasing 
understanding of the genetic basis of disease, enormous interest has emerged in the 
possibility of treating disease at the genetic level. Among promising therapeutic 
agents, oligonucleotides such as siRNA, antisense, and microRNA antagonists and 
mimics stand out for their superior specificity and ease of use [1, 2]. Antisense has 
already entered clinical practice while numerous clinical trials of siRNA and 
microRNA-based drugs are underway [3, 4].  
 There is a widespread consensus in the field that the full potential of 
oligonucleotides as therapeutic agents will not be realized until better methodologies 
for targeted delivery to cells and tissues are developed. Numerous approaches have 
been developed over the years including chemical modification of the oligonucleotide 
[5, 6], viral vectors [7, 8], polymer carriers [9, 10], and nanoparticles [11-13]. 
Oligonucleotide modification and viral vectors are both relatively costly and time-
consuming strategies. Viral vectors, in particular, also suffer from high toxicity and 
immunogenicity. Polymeric carriers such as cationic compounds are relatively cost-
efficient, have low toxicity, and have potential for large-scale production, making 
them promising candidates for oligonucleotide delivery. Nanoparticle delivery 
vehicles make use of polymeric carriers by employing them as a coating over an 
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inorganic nanoparticle that may be used for targeting and tracking, thus creating a 
multifunctional delivery system.  
 Cationic polymers have emerged as a leading candidate for oligonucleotide 
delivery given its advantages of biocompatibility, low cost, scalability, and versatility 
(can load any oligonucleotide cargo by simple mixing). Moreover, they can be used 
to coat a nanoparticle for multifunctionality. A major limitation in their use, however, 
is their relatively lower transfection efficiency relative to viruses. Numerous studies 
have been published to date demonstrating utility of a wide variety of polymeric 
carriers but little has been done to directly compare polymers to evaluate factors for 
rational design [14-19].  
 Cationic polymers successfully deliver oligonucleotides due to a variety of 
properties. They bind DNA/RNA through electrostatic interaction, facilitate cell 
internalization through electrostatic adsorption on the cell membrane, and provide 
proton buffering capacity for endosomal escape through the proton sponge effect 
[20-22].  
 The amine groups responsible for these cationic and proton buffering 
capacities, however, need to be balanced. The polymer needs to have many high 
pKa (pKa > 7) amine groups to provide a strong cationic charge for oligonucleotide 
binding but not too strong for intracellular release. These high pKa amines, however, 
need to be balanced with lower pKa amines that provide proton buffering capacity. 
Past studies examining this balance by testing combinatorial libraries of polymers 
containing varying ratios of high pKa and low pKa cationic groups have only 
examined plasmid DNA (pDNA) rather an oligonucleotides [23, 24]. Moreover, these 
studies covered free polymers rather than polymer-coated inorganic nanoparticles. 
These distinctions are important because pDNA is significantly larger than 
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oligonucleotides and must be delivered to the nucleus rather than to the cytoplasm 
[25]. Also, free polymers will have amine functional groups located somewhat 
uniformly throughout the entire polymer whereas polymer-coated nanoparticles may 
have amine functional groups only on the surface of the particle, which may affect 
how the particles interact with the biological environment. 
 In this chapter, we will prepare iron oxide nanoparticles containing 
combinations of high pKa and low pKa amines. We will begin by evaluating the pH 
behavior of these amine molecules. The amines will then be reacted with iron oxide 
nanoparticles to create a panel of SPIONs containing different amine combinations. 
These particles will be characterized and their ability to bind DNA will be evaluated in 




 Water-soluble 50 nm iron oxide nanoparticles with a glucuronic acid matrix 
coating were purchased from Chemicell Inc (Berlin, Germany). Particles had a core 
size of approximately 10 nm (from TEM) and an overall hydrodynamic size of 
approximately 40 nm (from DLS), which were independently obtained. Secondary 
amine (N-Methyl-1,3-diaminopropane), tertiary amine (3-(dimethylamino)-1-
propylamine), imidazole (1-(3-Aminopropyl)imidazole), DPTA (N,N-
Dimethyldipropylenetriamine), and EDC (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide) were purchased from Sigma-Aldrich (St. Louis, 
MO). Fluorescein-labeled DNA with the sequence 5’-6FAM-





 Glucuronic acid-coated iron oxide nanoparticles were conjugated to amine 
molecules by carbodiimide reaction. 50 ul of 50 nm particles were added to a 
750,000-fold molar excess of amine molecules to particles in 0.2 M borate buffer. 
The pH was adjusted for each reaction mixture to approximately pH 5.5 after 
addition of amines. EDC was then added and the reaction mixture was allowed to 
incubate at room temperature for 1 hour. The pH of the mixture was raised to >8 by 
addition of NaOH to quench any O-acylisourea intermediates and incubated for 10 
minutes. The zeta potential was then measured for each particle sample (Zetasizer 
Nano ZS90, Malvern Instruments, Worcestershire, UK). Sequential lowering the pH 
to 5.5, addition of EDC, raising the pH > 8, and zeta potential measurement was 
repeated until the zeta potential stabilized for all samples, indicating saturation of the 
nanoparticle surface with amines. DLS measurements of iron oxide samples were 




 For TEM observation of unconjugated nanoparticles, 5 uL of the samples 
were pipetted onto a carbon TEM grid. The solvents were slowly wicked away with 
filter paper after 15 minutes and the grids were then counterstained with a 1% 
phophotungstic acid solution (pH adjusted to 6) for 30 seconds. The staining solution 
was slowly wicked away and allowed to dry. Grids were then imaged by TEM (H-




 For DNA binding studies, 6pmol of fluorescein-labeled DNA was incubated in 
1X MOPS buffer (pH 7) with varying amounts of amine-conjugated SPION. The 
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particles and DNA were allowed to complex overnight (12-18hours) at 4C. For 
aggregation/particle sizing experiments, the hydrodynamic sizes of the complexes 
were then determined by DLS. For DNA binding capacity experiments, the 
complexes were mixed with a 5X bromophenol blue loading buffer (400 ul solution 
prepared by mixing 200 ul 10X MOPS, 150 ul 1% bromophenol blue in water, and 50 
ul 50% glycerol) and loaded onto a 0.8% agarose/0.1% Tween-20 gel in 1X MOPS. 
Gels were run for 15min at 120V in a and subsequently imaged with a UV 
transillumination system (BioRad, Hercules, CA). 
 
 
4.3 Results and Discussion 
Amine Molecules 
 Studies have shown that polymers containing amine groups are useful as 
vectors for cellular delivery of nucleic acids both for their ability to complex DNA and 
to effect cytoplasmic entry by the proton sponge effect. Different amine molecules, 
however, have different charge and buffering properties that may influence 
performance as oligonucleotide transfecting agents. Past studies examining different 
amine groups have supported the notion that a combination of both cationic and pH 
buffering groups may produce an optimal delivery vehicle for plasmid DNA [24, 26-
28]. Leong et al. demonstrated that the transfection efficiency of a polymer 
containing only high pKa amines could be enhanced 85-fold when co-delivered with 
chloroquine, a lysosomotropic agent, suggesting that endosomal escape was the 
rate-limiting step for this polymer [26]. Putnam et al. demonstrated that increasing 
the imidazole content of high pKa amine-containing polymers could enhance 
delivery; however polymers containing only imidazole showed some but suboptimal 
transfection efficiency, presumably due to weak pDNA binding [24]. 
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 To study the utility of various types of amine molecules, a total of four 
different amine-containing molecules were evaluated: a secondary amine molecule 
(2A), a tertiary amine molecule (3A), a molecule containing both secondary and 
tertiary amines (DPTA), and an imidazole- containing molecule (I) (Figure 4.1). 
Secondary and tertiary amines both have high pKas in the range of pH 8-10, with 
tertiary amines having a slightly lower pKa than secondary amines. Imadazoles have 




Figure 4.1: Molecular structures of amine molecules to be conjugated to 
nanoparticles. 2A = N-Methyl-1,3-diaminopropane; 3A = 3-(dimethylamino)-1-




 Figure 4.2 shows titration curves of the free molecules. Free amines were 
placed in pure water. The solution had an initially high pH due to the basic properties 
of the amine molecules. As HCl was added to the solution, the pH only exhibited 
small decreases as the amines were able to buffer pH through nitrogen protonation. 
Once the buffering capacity of the amine molecules are reached (i.e. when all the 
nitrogens are protonated) additional acid added to the solution will cause the pH to 
drop sharply. Interestingly the secondary and tertiary amines have very similar 
titration curves. They have relatively high pKas, around pH 9, consistent with data 
reported in the literature. The titration curves show that at physiological pH 
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conditions, these molecules will have very little buffering capacity, as most of the 
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Figure 4.2: Titration curves for amine molecules.  
 
 The titration curve for imidazole has two sharp drops, corresponding to the 
different pKas of the two nitrogens in the five-membered ring. The first nitrogen has 
a high pKa, around pH 9, similar to the pKas of the secondary and tertiary amines. 
The second nitrogen, however, has a lower pKa, around pH 6.5-7. Imidazole will thus 
have some cationic nature, due to one nitrogen, but will also have a significant 
proton buffering capacity due to the second nitrogen. As we go down titration the 
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curve from physiological pH the pH does not change significantly with additional 
acid. It is only at around pH 5.5 that the buffering capacity of imidazole is exhausted.  
 Although DPTA has two amine groups (besides the primary amine), like 
imidazole, the pKas for the secondary and tertiary amines are similar enough that 
two pH drops are not observed. Instead, only one is observed. The relative shape of 
DPTA’s titration curve is very similar to that of 2A and 3A. The pKa is observed to be 
similar, although perhaps slightly lower, at around pH 8.5-9 with a sharp pH drop 
occurring at around pH 6.5-7, which is also slightly lower than for 2A or 3A. DPTA is 
thus still primarily a cationic molecule with much less buffering capacity than 
imidazole. The fact that it has both a 2A and 3A, however, will be useful in 
investigating the effect of additional cationic groups on oligonucleotide transfection. 
 The titration data is consistent with the expected pKas for each of the 
molecules and highlights the weak buffering capacity of the 2A, 3A, and DPTA 
molecules at endosomal pH (pH 5-6.2). Imidazole, on the other hand, has a high 
buffering capacity at this pH. 2A, 3A, and DPTA, however, are highly cationic 
whereas imidazole is less so. Because the secondary and tertiary amine molecules 
have very similar titration curves, we decided to use only one of the two, 3A, for 
subsequent studies. 
 
Iron Oxide Nanoparticles 
 
 Commercially available carboxyl-coated iron oxide nanoparticles were used 
as the base delivery vehicle to which the amine groups were attached. Particles 
were composed of magnetite (Fe3O4) with a glucuronic acid polymer matrix coating 
which contain carboxyl groups available for conjugation. TEM indicated the 
magnetite core was approximately 10 nm in diameter (Figure 4.3). DLS 
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measurements showed the particles had a significantly higher hydrodynamic 
diameter of 38.8 nm. The difference in TEM and DLS sizes can be attributed to a 
relatively thick polymer coating. Particles had a charge of -20.2 mV, consistent with 




Figure 4.3: Characterization of unconjugated iron oxide particles. Schematic image 
showing particles coated carboxyl groups. Zeta potential of was -20.2mV. TEM and DLS 




 Three amine molecules—3A, DPTA, and I—were combined in pairs in ratios 
of 25%/75%, 50%/50%, and 75%/25% (Table 4.1). These amine combinations, 
along with the pure amines themselves, were then reacted in excess with 
commercially available carboxyl-coated iron oxide nanoparticles using carbodiimide 
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chemistry (EDC) to generate a panel of 12 different nanoparticle coatings (Figure 
4.4). EDC is frequently used to conjugate biomolecules such as antibodies and small 
molecule ligands to nanoparticles for targeting purposes. The chemistry, however, is 
difficult to control and does not give a 100% yield. This is appropriate for conjugating 
targeting molecules to nanoparticles because the amount of molecules conjugated is 
not as important as that molecules are conjugated at all; but this becomes an issue 
for this study because we want to know the composition of the nanoparticle surface. 
Performing the reaction only one time would yield a surface coating that is a mixture 
of amines and carboxyls in unknown ratios. To prevent having an unknown carboxyl 











Figure 4.4: Reaction scheme for conjugating amine molecules onto SPIONs. 
 
 
The extent of reaction was monitored by measuring zeta potential. Because 
carboxyl groups are anionic and amine groups are cationic, the surface charge will 
increase as the reaction progresses. Over iterative reactions, the charge should 
eventually plateau at a positive value, indicating saturation of the iron oxide surface 
with amines. Figure 4.5 shows our results. Unconjugated nanoparticles had a 
surface charge of -20.2 mV, consistent with the anionic character of the carboxylic 
acid coating. As the amines were conjugated the zeta potential became positive and 
eventually plateued around +20mV. 
Interestingly, there did not appear to be a significant difference in the plateau 
charges for the different particles. As was discussed earlier, imidazole is less 
cationic than tertiary amines and would be expected to have a lower positive charge. 
It should be noted, however, that the zeta measurements were performed in 
deoinized water (pH 5). This acidic pH is below the pKa of all amine molecules tested 
and thus all amines should be fully protonated, eliminating charge differences due to 
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differing pKa. Also of note, there did not seem to be a large difference in saturated 
surface charge for the amine coatings with only one amine group per molecule (3A) 
versus those with two amine groups per molecule (DPTA or I). This is may be due to 
the fact that zeta measures only the surface charge. The second amine of DPTA and 






























Figure 4.5: Zeta potential measurements to evaluate extent of amine reaction onto 






 Hydrodynamic sizes of reacted particles were determined by dynamic light 
scattering to see if differences in composition affected size (Figure 4.6). While there 
was some variability in particle sizes, the differences were within measurement error. 
Coating composition thus did not seem to affect particle size and particles remained 
discrete at around 35-40 nm. Interestingly, size did not change appreciably after 
amine conjugation, which involved a charge reversal. The sizes of the different 
amine particles also did not seem to differ significantly, even though some particles 








































































 With the particles prepared and characterized, we investigated the DNA 
binding properties of the particles. For transfection to occur, the iron oxide 
nanoparticles need to bind to the DNA oligonucleotides. As stated before, the 
advantage of using amines is they are cationic and can be used to bind DNA 
electrostatically by its negatively charged phosphate groups. To study 
oligonucleotide binding properties, particles were incubated with a fluorescein-
labeled DNA oligonucleotide at DNA-IO ratios of 500:1, 200:1, 100:1, 50:1, 20:1, and 
10:1. The DNA oligonucleotide contained 21 bases and had sequence identicality to 
the DNA used for transfection in the following chapter. After incubating the 
nanoparticles and DNA, samples were loaded onto an agarose gel and 
electrophoresis was performed. Results for all 12 nanoparticle samples are shown in 
Figure 4.7. 
 The first lane in all gels contains only fluorescein-labeled DNA. As expected, 
the DNA migrates down the gel towards the cathode due to its negatively charged 
phosphate groups. The remaining bands contain an identical amount of DNA but 
have increasing amounts of nanoparticles to match the labeled ratios. At a 500:1 
DNA:IO ratio, the DNA band is still present, indicating that most of the DNA is 
unbound. As the relative amount of DNA to nanoparticle is decreased, the DNA band 
starts to disappear, indicating DNA binding by the iron oxide. At a 200:1 ratio, many 
of the gels contain a smear, possibly due to electrostatic interaction of the particles 
with the DNA that is strong enough to retard but not completely bind the 
oligonucleotides. At a 50:1 ratio, DNA seems to be completely bound for all 
nanoparticle samples tested. Indeed, while a 100:1 ratio seems sufficient in most of 
the gels, a faint band does appear for some, particularly for the particles having a 
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high imidazole content (e.g. 100I and 75 I/25 3A). It should be noted that at low 
DNA-IO ratios, the DNA band migrated towards the anode whereas the iron oxide 
cores remained inside the well. The polymer coating was thus probably stripped off 
of the nanoparticles cores while remaining bound to the DNA.  
 Determining DNA binding capacity by this method is important both for 
ascertaining the amount of iron oxide needed to fully bind DNA for our transfection 
studies in the next chapter as well as for giving some idea of the relative DNA 
binding strengths of the particles. The data may suggest that the particles containing 
high levels of imidazole have somewhat weaker oligonucleotide binding potentially 
due to its lower cationic properties relative to 3A or DPTA at the neutral pH at which 
these experiments were performed. More importantly, however, the data shows that 
the DNA binding capacity of all particles tested is at least 50 oligonucleotides per 




Figure 4.7: Gel electrophoresis assays showing oligonucleotide loading onto 
amine-coated SPIONs. Three gels in red box at top indicate particles containing only 
one type of amine each. Numbers preceding D/I/3A indicate percentages of each amine 
molecule on the coating. 
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 Having performed the DNA binding experiments and having determined the 
binding capacity of our particles, we wanted to verify that addition of the DNA does 
not cause the iron oxide nanoparticles to aggregate. Because the positive and 
negative charges exist throughout both the iron oxide nanoparticles and DNA, 
respectively, there is the potential for a single DNA to be bound by multiple 
nanoparticles, causing aggregation, which may compromise later cellular 
experiments. Aggregation is particularly likely when using high DNA:IO ratios such 
as the 50:1 that the gel experiments suggested. To assay for particle aggregation in 
the presence of DNA, DNA and 100%3A iron oxide nanoparticles were again 
incubated at various ratios. The hydrodynamic sizes of the complexes were then 
determined by DLS. Figure 4.8 shows that for all ratios tested, including a 100:1 
DNA:IO ratio, no aggregation was observed. Hydrodynamic sizes of DNA:IO 
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complexes did not differ significantly from the size of pure 100%3A particles alone. 


































Figure 4.8: Dynamic light scattering measurements of DNA-SPION complexes. 





 We have demonstrated in this chapter that we can prepare different amine-
coated SPIONs using EDC reaction. We have confirmed successful reaction by 
measuring the zeta potential and observing its increase to around +20 mV. 
Conjugated particles were stable and discrete, demonstrated by their hydrodynamic 
diameters being unchanged from their preconjugated forms. Further, they remained 
stable even after addition of negatively-charged oligonucleotides. Gel binding studies 
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A COMBINATORIAL EVALUATION OF AMINE COATINGS FOR 
NANOPARTICLE DELIVERY OF ANTAGOMIR 
 
5.1 Introduction 
 MicroRNA are short, processed, RNA molecules around 22 nucleotides in 
length that can control gene function through mRNA degradation, translation 
inhibition or chromatin-based silencing mechanisms [1, 2]. Discovered in the 1990’s, 
this class of biomolecule has gained attention as an important regulator as more 
than 1000 have been identified in humans so far [3]. The potential involvement of 
miRNA in human disease might be inferred from even the first studies of miRNA 
function. The lin-4 and let-7 phenotypes observed in C. elegans can be described as 
proliferative defects and the roles of bantam and miR-14 in D. melanogaster also 
points to defects in proliferation [4-8]. Indeed, miRNA have been found to be 
involved in development, proliferation, differentiation, and apoptosis, all functions 
important in several diseases, including cancer [9-12]. MicroRNAs have been found 
to play oncogenic and tumor suppressor roles [13] and are de-regulated in many 
primary human tumors [14-17]. These studies suggest that miRNA may be promising 
as a therapeutic target. In fact, both miRNA antagomirs and mimics have been 
reported in the literature [18-21]. As for other oligonucleotide drugs, miRNA-based 
drugs require a delivery method for their full promise to be realized [22]. 
 In this chapter, we will use the panel of SPIONs prepared in Chapter 4 and 
evaluate their efficacy in delivering an antagomir against a cancer-related microRNA, 
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miR-222. This represents the first study demonstrating the use of nanoparticles for 
delivering antagomirs into cells. Results will shed light on optimal amine 
combinations for antagomir delivery, which could have implications for delivery of 
other oligonucleotides such as siRNA and antisense. We will also use TEM and 




 PC-3 cells were grown in RPMI 1640 buffer and plated on a 96-well plate at 
about 5000 cells/well. Delivery agents were prepared by the following. IO 
nanoparticles were incubated with LNA antagomirs against miR-222 at a 1:50 
IO:LNA ratio overnight in PBS. Antagomirs had the sequence 5’- 
accCagTagCcaGatGtaGct-3’ where capitalized bases are LNA-modified (Integrated 
DNA Technologies, Coralville, IA). PEI-LNA complexes were prepared by incubating 
PEI with LNA at an N:P ratio of 8 overnight. Following overnight incubation, 
complexes were diluted in Opti-MEM (Invitrogen). LNA transfection by Lipofectamine 
2000 was also performed according to the manufacturer’s instructions, with liposome 
complexes prepared the day of transfection.  
 After 24 hours of cell growth on the 96-well plate, cells were washed in PBS 
and delivery agents were added to yield a 40nM LNA concentration in Opti-MEM 
buffer (Invitrogen). Cells were incubated with delivery agents for 4hrs before washing 
in PBS. Twenty-four hours post-transfection, cells were lysed and RNA enriched for 
short sequences was collected using the miRvana RNA Isolation Kit (Ambion). All 
transfections were carried out in triplicate. 
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Real-time PCR and Data Analysis 
 
 RNA samples were reverse transcribed using the Taqman®  MicroRNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Real-time PCR was 
the performed on the reverse transcription product using the TaqMan MicroRNA 
Assay according to the manufacturer’s instructions (Applied Biosystems). Data was 
normalized by U6B small nuclear RNA as an endogenous control (RNU6B, from 
Applied Biosystems, Foster City, CA). After normalizing expression data to RNU6B, 
data was further normalized to no transfection control. Student t-test was performed 




 For TEM examination of the monolayer cells, cells cultured in 6-well tissue 
culture plates were incubated with antagomir-nanoparticle complexes for four hour 
before being replaced with full media. Cells were fixed 24 hours post-transfection by 
incubating overnight in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) at 
4C. Cells were then washed with the same buffer and post-fixed in 1% buffered 
osmium tetroxide, dehydrated through a graded ethanol series to 100%, and 
embedded in Eponate 12 resin (Ted Pella Inc., Redding, CA). Ultrathin sections 
were cut on a Leica UC6rt Ultramicrotome (Leica Microsystems, Bannockburn, IL) at 
70-80nm, and counter-stained with 4% aqueous uranyl acetate and 2% lead citrate. 
Sections were examined using a Hitachi H-7500 transmission electron microscope 
(Hitachi High Technologies of America, Inc., Pleasanton, CA) equipped with a Gatan 






Bulk Fluorescence Measurements 
 
 Bulk absorbance measurements were performed using a spectrophotometer 
(Shimadzu UV-2401PC, Kyoto, Japan). Bulk emission measurements were 
performed using a standard fluorometer (FluoMax, Jobin Yvon, Edison, NJ). 
Fluorescence quenching of TYE665-labeled antagomir by SPIONs was performed 
by comparing emissions of a volume of fluorescent antagomir-SPION complex and a 




 For fluorescence imaging studies, nanoparticle-LNA complexes were 
prepared and transfection performed as per the Transfection method described 
above, except using a TYE665-conjugated LNA oligonucleotide in place of the 
regular LNA and growing cells in LabTek II chamber slides rather than a 96-well 
plate. Cells were washed in 1X PBS 4 hours after nanoparticle-LNA complex 
exposure and then incubated with full medium. Twenty-four hours post-transfection, 
cells were washed twice briefly in PBS and fixed and permeabilized for 20 min in 4% 
paraformaldehyde supplemented with 0.1% Triton X-100. After briefly washing twice 
in PBS, blocking buffer (5% goat serum/2% BSA in 1X PBS) was added for 1 hour. 
Cells were washed again twice for 5 min each in 0.2% BSA/1X PBS before adding 
primary antibody against LAMP1 (Abgent, San Diego, CA) at a 6.25 ug/ml 
concentration diluted in 1% BSA/1X PBS for 45 minutes. Cells were washed 2X5 
min again in 0.2% BSA/1X PBS and then incubated in Alexa Fluor 568-conjugated 
goat anti-rabbit secondary antibody (Invitrogen, Carlsbad, CA) at a 5ug/ml 
concentration in 2% BSA/1X PBS. Cells were then washed 2X5min in PBS before 
DAPI counterstaining. Slides were then mounted and coverslipped for imaging on a 
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Zeiss LSM 510 META confocal microscope. Images were analyzed using NIH Image 
J software [23]. 
 
5.3 Results and Discussion 
 To study the transfection efficiencies of our panel of nanoparticles, PC-3 
prostate cancer cells were incubated with complexes of antagomir against miR-222 
with each of the nanoparticles. miR-222 is a putative oncogenic microRNA that 
negatively regulates the p27 tumor suppressor protein [24]. Past studies have 
identified miR-222 overexpression in a variety of cancers, the majority of which is 
also known to be characterized by p27 loss or mutations. miR-222 overexpression 
has been identified in glioblastoma [25, 26], prostate carcinoma [24], solid tumors of 
the colon, pancreas, and stomach [27, 28], and are strongly-upregulated in papillary 
thyroid carcinoma and chronic lymphocytic leukemia [24, 29-31]. In a cell line model, 
miR-222 was found to be overexpressed in the PC-3 cellular model of aggressive 
prostate carcinoma, as compared with LNCaP and 22Rν1 cell line models of slowly 
growing carcinomas. Antagonism of miR-222 in PC-3 caused a reduction in 
clonogenicity [24]. 
The antagomir used had perfect complementarity to miR-222 and contained a 
number of locked nucleic acid (LNA) modified nucleotides (Figure 5.1). LNA 
nucleotides are chemically modified DNA nucleotides with a 2’-O,4’-C-methylene 
bridge in the ribose ring (Figure 5.1B). This bridge conformationally locks the C3’-
endo sugar conformation, which is ideal for RNA recognition [32, 33] (Figure 5.1A). 
LNA modifications increase the melting temperature of the antagomir:RNA duplex, 
which is important because binding strength is relatively weak for unmodified 
DNA:RNA duplexes with such short lengths [34, 35]. We designed our LNA 
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according to recommendations of spacing LNA-modified nucleotides at every third 
base and limited the number of LNA-modifications to keep the melting temperature 







Figure 5.1: Chemical structures of LNA-modified nucleotides and miR-222 
antagomir. (A) C2’-endo and C3’-endo conformations of ribose ring. C3’-endo is ideal 
for base pairing with RNA. (B) LNA structure showing ribose locked in C3’-endo 






 With the probe designed, nanoparticle-antagomir complexes were incubated 
with PC-3 cells. The real-time PCR results are shown in Figure 5.2. Data was 
normalized to the no transfection control. The data shows that the different particles 
had different transfection efficiencies, with miR-222 expression levels being 20-70% 
that of the control. Polyethyleneimine (PEI), the current standard polymeric gene 
delivery vector, had a miR-222 expression of around 73% of control, similar to the 
efficiencies reported by others for this compound [38]. 100%I coated nanoparticles 
seemed to perform the best, with a transfection efficiency of close to 80%. In 
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contrast, the particles containing 100%D and 100%3A seemed to perform the worst, 
with efficiencies around 50%. Interestingly, 100%D and 100%3A did not exhibit a 
statistically significant difference in transfection efficiency. The remaining particles 
seemed to vary in between these two values. It should be noted that all the particles 





































Figure 5.2: MiR-222 expression after antagomir transfection with amine-coated 
SPIONs. Data shows comparative cT values, with RNU6B as endogenous control, 




 The data shows that imidazole performs better than either tertiary amine or 
DPTA, suggesting that the enhanced proton buffering ability inherent to imidazole 
enhances transfection. Moreover, the additional cationic group present on DPTA 
does not seem to significantly affect miR-222 antagonism. This is further illustrated 
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in Figure 5.3, which compares the relative transfection efficiencies of binary 
combinations of amines of different ratios. Figure 5.3A shows that 100%DPTA gives 
a relatively high miR-222 expression. As imidizole is added, replacing DPTA, miR-
222 expression appears to decrease, reaching a minimum at 100%I. The expression 
difference between 100%DPTA and 100%I is statistically significant. While there 
may be a decrease in expression as imidazole is increased, the differences among 
the intermediate groups were mostly not statistically significant. Hence, it is not 
possible to conclude whether incremental improvements in miR-222 antagonism 
could be observed with incremental increases in imidizole content. We can conclude, 
however, that 100%I performs better than 100%D.  
 Similarly, Figure 5.2B shows the effect of increasing imidazole content 
relative to tertiary amine. Again, 100%3A gives a relatively high miR-222 expression 
which is improved with addition of imidazole. In fact, 100%I has about half the miR-
222 expression of 100%3A, with the difference being statistically significant. The 
intermediate particles containing a mixture of imidazole and tertiary amine did not 
exhibit statistically significant differences from one another or from the single amine 
particles.  
 While the addition of proton buffering groups enhances miRNA antagonism, 
the addition of cationic groups appears to have no effect. Figure 5.3C shows the 
effect of replacing 3A by DPTA. These two molecules differ only by the fact that 
DPTA contains an additional secondary amine, which should increase the cationic 
character of this molecule, relative to 3A. Moving left to right on Figure 5.3C, 3A is 
replaced by DPTA, meaning that additional secondary amines are added onto the 
particles. MiR-222 expression, however, remains relatively constant at 50-60% and 






































Figure 5.3: MiR-222 expression after antagomir transfection grouped by SPION 







































































 Having verified the efficacy of the iron oxide nanoparticles on microRNA 
antagonism, we investigated the transfection process further by electron microscopy. 
We selected 100%D as a model particle and incubated them with PC-3 cells again. 
Cells were fixed 24 hours after nanoparticle exposure and imaged by TEM. Images 
show that the particles successfully entered cells and were consistently localized in 
endosomes. Figure 5.4A shows an electron micrograph of a portion of one cell. 
Several distinct dark regions containing electron-dense material can be seen. 
Figures 5.4B and C are enlarged images showing regions of Figure 5.4A. Large 
amounts of iron oxide nanoparticles can be clearly seen localized in late endosomal 
compartments, which can be identified by the slightly darker shade endued by 
counter-staining. The numbers of particles inside the endosomes varied 
considerably from endosome to endosome. Nevertheless, it appeared that 
endosomes containing nanoparticles had some tearing or rupturing, as indicated by 
arrows. Normal endosomes are typically uniformly gray in color; however we 
observed several which had lighter spots near the endosome perimeter (Figure 5.4B 
and D), which may indicate some leakage of its contents. Moreover, the perimeter of 
many of the endosomes seemed to be torn. This was especially apparent in the 
bottom endosome in Figure 5.4C and in those in 5.4D, taken from another cell from 
the same sample. While apparent tearing and rupturing was observed extensively for 
endosomes containing nanoparticles—presumably due to the proton sponge effect—
nanoparticles were not clearly observed to leak outside endosomes into the cell 
cytosol, even at 24 hours post iron oxide exposure, which was the point at which the 




Figure 5.4: TEM images of PC-3 cells after transfection with 100%DPTA SPION. (B) 
and (C) are enlarged sections of (A). (D) represents another cell in the same sample. 
Arrows indicate sites of apparent endosomal breakage. 
 
 
 This observation was somewhat surprising because for the antagomirs to 
have an effect, they must escape from endosomes and enter the cytosol where they 
can bind to target microRNA. If the nanoparticles themselves did not leave 
endosomes, this would mean that the antagomirs had to dissociate from 




 We were able to determine the fate of the nanoparticles by TEM but the fate 
of the antagomirs was unclear. We thus used TYE665-conjugated antagomirs that 
were otherwise identical to those used in the transfection experiments and used 
them to follow antagomir fate through fluorescent imaging. TYE665 has similar 
spectra properties to Cy5 with a maximum absorbance at 557 nm and maximum 
emission at 563 nm. During delivery, fluorescently-labeled antagomirs (FLNA) will be 
electrostatically associated to 100%D iron oxide nanoparticles. Iron oxides, however, 
have a relatively broad and high absorption that includes the wavelength range of 
TYE665 emission (Figure 5.5). Because of the close association of the nanoparticles 
and antagomirs, it is possible that the iron oxides quench emission of the dye. This 
would prevent fluorescent imaging of the antagomir for as long as it is associated 
with the nanoparticle. 
 We thus incubated fluorescently-labeled antagomirs with 100%D iron oxide 
nanoparticles and assayed any change in emission intensity. Figure 5.6 shows the 
emission of antagomirs alone along with the emission of antagomirs incubated with 
100%DPTA nanoparticles. Results show that emission is significantly decreased 
when the antagomirs are associated with the iron oxides. Indeed, integrated 
emission decreases by around 95% after nanoparticle association. We thus expect 
that when associated to a delivery vector, antagomirs will not be visible by 
fluorescent imaging. Fluorescent signals should  thus correspond to antagomirs that 








































































Figure 5.6: Emission of free FLNA and FLNA complexed with 100% DPTA SPION. 
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 Fluorescently-labeled antagomirs were thus delivered in complex with 
100%DPTA iron oxide nanoparticles. Cell samples were fixed at various points in 
time and imaged to see localization of the oligonucleotide probes. Figure 5.7A shows 
composite images of DAPI (blue) and TYE665 (red) filters at 5min, 2 hours, 4 hours, 
and 24 hours after introduction of the delivery complexes to PC-3 cells. Consistent 
with our result showing quenching of the fluorescent tag by the iron oxide carrier, 
shortly after delivery no signal was detected. If no quenching were to occur, we 
would have expected to observe TYE665 signal along the perimeter of the cell at the 
5 min time point as the particle-probe complexes should bind electrostatically to the 
negatively charged plasma membrane, similar to the results observed in Appendix A. 
Indeed, no TYE665 signal was observed in the 5min, 2 hour, or 4 hour time points. 
At 24 hours, however, red signals could be detected inside the cells. Figure 5.7B 
shows an enlarged region of the 24 hour image from Figure 5.7A, overlaid with a 
LAMP1 lysosomal stain (green). Red signals—corresponding to the fluorescently 
tagged antagomir—are visible, indicating dissociation of the antagomir from the iron 
oxide nanoparticle. In addition, this signal does not colocalize with the green 
lysosomal stain, indicating that the oligonucleotides have escaped from the ruptured 
endosomes. In sum, this data suggests that antagomirs are able to dissociate from 
their nanoparticle carriers inside the cell and migrate out of ruptured endosomal 
compartments into the cell cytosol. This intracellular dissociation takes place at least 




Figure 5.7: Confocal imaging of cells transfected with 100% DPTA SPION and 
FLNA. (A) Imaging of cells fixed at different time points showing only DAPII (blue) and 
FLNA (red) channels. (B) Zoom in of 24hr image with LAMP1 (green) overlay. 
 
 
 In conclusion, we have demonstrated the efficacy of amine-coated iron oxide 
nanoparticles for the intracellular delivery of antagomirs against miR-222. The 
particles are able to enter cells and become sequestered in endosomal 
compartments. They are able to rupture endosomes, presumably through the proton-
sponge effect, but do not seem to leave the endosomes themselves. Instead, the 
antagomirs appear to dissociate from their nanoparticle carriers and escape alone 
into the cytosol where they may antagonize their microRNA targets. Overall we have 
observed target microRNA expression to decrease up to around 75%. Differences in 
miR-222 antagonism were observed for particles containing different amine coatings, 
with imidazole-containing particles performing superior to tertiary amine- or DPTA-
containing particles. The exact reason for this observed performance difference is 
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yet unclear although it is probably owing to the chemical properties of imidazole, with 
its relatively lower pKa and thus improved proton buffering ability and lower cationic 
charge at neutral pH. These properties may render imidazole an enhanced ability to 
rupture endosomes through the proton sponge effect or to release antagomirs into 
the cell relative to its higher pKa counterparts.  
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DETERMINING THE EFFECT OF IRON OXIDE NANOPARTICLE 
SIZE ON ANTAGOMIR DELIVERY 
 
6.1 Introduction 
 Size is one of the key features of nanotechnology and gives rise to the unique 
properties of this class of material. It enables materials to interact specifically with 
biological molecules and structures and to have properties distinct from their bulk 
phase, such as fluorescence in semiconductor quantum dots or 
superparamagnetism in iron oxide nanoparticles [1-3]. Even within the nanometer 
range, however, size is an important factor that influences how materials behave, 
particularly in drug delivery applications. Size has been reported to influence almost 
every aspect of particle function including degradation, flow properties, clearance, 
biodistribution, level of uptake, and uptake mechanisms [4-12]. For instance, studies 
have shown that smaller nanoparticles (< 20 nm) can be excreted renally, medium 
sized nanoparticles (30-150 nm) have accumulated in the bone marrow, heart, 
kidney and stomach, while large particles (150-300 nm) accumulate in the liver and 
spleen by the reticuloendothelial system (RES) [9, 13-18]. This has led to a focus on 
the use of particles smaller than 100 nm for optimal drug delivery applications. 
 Past studies have also indicated size effects of nanoparticles at the cellular 
level, specifically with regards to intracellular uptake. Using Poly(lactic-co-glycolic 
acid)-copolymer nanoparticles to deliver pDNA, Amidon et al. reported seeing 
highest uptake for particles with a mean diameter of 100 nm [19]. Labhasetwar et al. 
showed using another cell line that cellular uptake for these same particles was 
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highest for particles with mean diameters of 70 nm as compared to those with mean 
diameters of 200 nm [20]. Yao et al. prepared PEI nanogel-pDNA complexes of 38, 
75, 87, 121, 132, and 167 nm and found complexes of 75 nm and 87 nm exhibited 
the highest transfection efficiencies [21-23].  
 Studies investigating how size affects uptake have also been performed for 
inorganic nanoparticles. Chan et al. evaluated intracellular uptake of 14, 50, and 74 
nm anionic gold nanoparticles and reported 50nm particles yielding the best 
intracellular uptake [24]. Xia et al., on the other hand, evaluated 15 and 45 nm gold 
nanospheres and 33 and 55nm gold nanocages and reported that the smaller 
particles had superior cellular uptake for both nanospheres and nanocages, 
regardless of nanoparticle coating [25]. The conflicting results of these two studies 
may be due to confounding factors such as nanoparticle coating, adsorption of 
serum proteins onto the nanoparticles, and cell type. Chan et al. used negatively 
charged citrate coated gold, which is not able to enter cells due to its charge and can 
only enter once coated with serum proteins. Xia et al., on the other hand, used a 
positively charged poly(allylamine hydrochloride) coating.  
 It is clear that further studies need to be conducted to evaluate how 
nanoparticle size affects internalization and, more specifically, nucleic acid 
transfection. In this chapter, we will prepare and use DPTA-coated iron oxide 
nanoparticles with hydrodynamic diameters of 40, 80, 150, and 200nm to evaluate 
how nanoparticle size affects antagomir delivery. We will begin by reacting the 
carboxyl-coated SPIONs with DPTA, monitoring the reaction progress, and 
characterizing the reacted particles, including their DNA binding properties. SPIONs 
will then be used to transfect PC-3 cells with antagomir against miR-222, a cancer-
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associated miRNA. TEM and fluorescence imaging will also be used to study the 




Water-soluble 50nm, 100nm, and 200nm iron oxide nanoparticles with a glucuronic 
acid matrix coating were purchased from Chemicell GmbH (Berlin, Germany). 
Particle sizes were found to differ slightly from the size reported by the manufacturer 
and varied depending on lot. Two different batches of 50nm particles were found to 
have sizes of approximately 40nm and 80nm. The 100nm particles had a 
hydrodynamic size of 150nm and the 200nm particles had a hydrodynamic size of 
200nm. DPTA was purchased from Sigma-Aldrich (St. Louis, MO). 
 
Particle Conjugation and Purification 
 
Glucuronic acid-coated iron oxide nanoparticles were conjugated to DPTA amine 
molecules by carbodiimide reaction. Amines were added at an excess to each of 40, 
80, 150, and 200 nm particles. Because addition of amines raised the pH, pH was 
adjusted back to 5.5 for each reaction mixture. EDC was then added and the 
reaction mixture was allowed to incubate at room temperature for 1 hour. The pH of 
the mixture was raised to >8 by addition of NaOH to quench any reactive O-
acylisourea intermediates and incubated for 10 minutes. The zeta potential was then 
measured for each particle sample (Zetasizer Nano ZS90, Malvern Instruments, 
Worcestershire, UK). Sequential lowering the pH to 5.5, addition of EDC, raising the 
pH > 8, and zeta potential measurement was repeated until the zeta potential 
stabilized for all samples, indicating saturation of the nanoparticle surface with 
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amines. Particles were purified by either ultracentrifugation at 100,000 rpm (40nm 
particles) or by magnetism (80, 150, and 200nm particles). Magnetic purification was 
performed by applying samples on a permanent neodymium block magnet (K&J 
Magnetics, Inc, Jamison, PA). DLS measurements were also performed on the 




 For DNA binding studies, 6pmol of fluorescein-labeled DNA was incubated in 
1X MOPS buffer (pH 7) with varying amounts of amine-conjugated SPION. The 
particles and DNA were allowed to complex overnight (12-18hours) at 4C. For 
aggregation/particle sizing experiments, the hydrodynamic sizes of the complexes 
were then determined by DLS. For DNA binding capacity experiments, the 
complexes were mixed with a 5X bromophenol blue loading buffer (400 ul solution 
prepared by mixing 200 ul 10X MOPS, 150 ul 1% bromophenol blue in water, and 50 
ul 50% glycerol) and loaded onto a 0.8% agarose/0.1% Tween-20 gel in 1X MOPS. 
Gels were run for 15min at 120V in a and subsequently imaged with a UV 




 PC-3 cells were grown in RPMI 1640 buffer and plated on a 96-well plate at 
about 5000 cells/well. Different sized IO nanoparticles were incubated overnight with 
LNA antagomirs against miR-222 at the following IO:LNA ratios, according to binding 
capacities determined in DNA binding experiments: 1:50 for 40 nm particles, 1:20 for 
80 nm particles, 1:200 for 100 nm particles, and 1:5000 for 200 nm particles. 
Antagomirs had the sequence 5’- accCagTagCcaGatGtaGct-3’ where capitalized 
bases are LNA-modified (Integrated DNA Technologies, Coralville, IA). Following 
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overnight incubation, complexes were diluted in Opti-MEM (Invitrogen) to 
appropriate concentrations for cell transfection.  
 After 24 hours of cell growth on the 96-well plate, cells were washed in PBS 
and delivery agents were added to yield a 40nM LNA concentration in Opti-MEM 
buffer (Invitrogen). Cells were incubated with delivery agents for 4hrs before washing 
in PBS. Twenty-four hours post-transfection, cells were lysed and RNA enriched for 
short sequences was collected using the miRvana RNA Isolation Kit (Ambion). All 
transfections were carried out in triplicate. 
 
Real-Time PCR and Data Analysis 
 
 RNA samples were reverse transcribed using the Taqman®  MicroRNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Real-time PCR was 
the performed on the reverse transcription product using the TaqMan MicroRNA 
Assay according to the manufacturer’s instructions (Applied Biosystems). Data was 
normalized by U6B small nuclear RNA as an endogenous control (RNU6B, from 
Applied Biosystems, Foster City, CA). After normalizing expression data to RNU6B, 
data was further normalized to no transfection control. Student t-test was performed 




 For TEM observation of conjugated nanoparticles, 5 uL of the samples were 
pipetted onto a carbon TEM grid. The solvents were slowly wicked away with filter 
paper after 15 minutes and the grids were then counterstained with a 1% 
phophotungstic acid solution (pH adjusted to 6) for 30 seconds. The staining solution 
was slowly wicked away and allowed to dry. Grids were then imaged by TEM (H-
600, Hitachi, Japan) operating at an acceleration voltage of 80 kV.  
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 For TEM examination of the monolayer cells, cells cultured in 6-well tissue 
culture plates were incubated with antagomir-nanoparticle complexes for four hour 
before being replaced with full media. Cells were fixed 24 hours post-transfection by 
incubating overnight in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) at 
4C. Cells were then washed with the same buffer and post-fixed in 1% buffered 
osmium tetroxide, dehydrated through a graded ethanol series to 100%, and 
embedded in Eponate 12 resin (Ted Pella Inc., Redding, CA). Ultrathin sections 
were cut on a Leica UC6rt Ultramicrotome (Leica Microsystems, Bannockburn, IL) at 
70-80nm, and counter-stained with 4% aqueous uranyl acetate and 2% lead citrate. 
Sections were examined using a Hitachi H-7500 transmission electron microscope 
(Hitachi High Technologies of America, Inc., Pleasanton, CA) equipped with a Gatan 
BioScan CCD camera. 
 
Bulk Fluorescence Measurements 
 
Bulk absorbance measurements were performed using a spectrophotometer 
(Shimadzu UV-2401PC, Kyoto, Japan). Bulk emission measurements were 
performed using a standard fluorometer (FluoMax, Jobin Yvon, Edison, NJ). 
Fluorescence quenching of TYE665-labeled antagomir by SPIONs was performed 
by comparing emissions of a volume of fluorescent antagomir-SPION complex and a 




 For fluorescence imaging studies, nanoparticle-LNA complexes were 
prepared and transfection performed as per the Transfection method described 
above, except using a TYE665-conjugated LNA oligonucleotide in place of the 
regular LNA and growing cells in LabTek II chamber slides rather than a 96-well 
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plate. Cells were washed in 1X PBS 4 hours after nanoparticle-LNA complex 
exposure and then incubated with full medium. Twenty-four hours post-transfection, 
cells were washed twice briefly in PBS and fixed and permeabilized for 20 min in 4% 
paraformaldehyde supplemented with 0.1% Triton X-100. After briefly washing twice 
in PBS, blocking buffer (5% goat serum/2% BSA in 1X PBS) was added for 1 hour. 
Cells were washed again twice for 5 min each in 0.2% BSA/1X PBS before adding 
primary antibody against LAMP1 (Abgent, San Diego, CA) at a 6.25 ug/ml 
concentration diluted in 1% BSA/1X PBS for 45 minutes. Cells were washed 2X5 
min again in 0.2% BSA/1X PBS and then incubated in Alexa Fluor 568-conjugated 
goat anti-rabbit secondary antibody (Invitrogen, Carlsbad, CA) at a 5ug/ml 
concentration in 2% BSA/1X PBS. Cells were then washed 2X5min in PBS before 
DAPI counterstaining. Slides were then mounted and coverslipped for imaging on a 
Zeiss LSM 510 META confocal microscope. Images were analyzed using NIH Image 
J software [26]. 
 
6.3 Results and Discussion 
 To investigate how nanoparticle size affects the transfection process, a panel 
of 4 nanoparticle sizes were evaluated: 40nm, 80nm, 150nm, and 200nm in 
hydrodynamic diameter (Figure 6.1). Particles were composed of inorganic 
magnetite cores coated with a glucuronic acid polymer coating, with the exception of 
the 200nm particles, which had cores composed of maghemite. TEM images 
showed that the 40nm and 80nm particles had cores which were approximately 10 
nm in diameter, indicating they had a relatively thick polymer coating. Zeta potential 
measurements showed a highly negative particle surface charge for all samples, in 
agreement with the carboxyl groups on the glucuronic acid polymer coating. Zeta 
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was less negative for the smaller particles (-20.2mV and -28.0mV for 40nm and 
80nm, respectively) and increased with particles size (-32.9mV and -36.2mV for 
150nm and 200nm, respectively).  
 
 




 To functionalize particles with transfection ability, they were reacted with 
DPTA, an amine molecule that we have previously demonstrated to be useful for 
oligonucleotide transfection. Figure 6.2 shows the reaction procedure. Carboxyl-
coated nanoparticles were reacted with DPTA through carbodiimide chemistry. The 
reaction should yield particles containing amide linkages to both a secondary and 
tertiary amine. Because EDC chemistry is difficult to control and does not give a 
100% yield, we peformed the reaction iteratively until almost all the carboxyl groups 
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had been reacted. This was important to ensure that different levels of amine coating 
was not a variable in our analysis. 
 
 
Figure 6.2: Reaction scheme for modifying carboxyl-coated SPIONS with DPTA 
amine molecules. Reaction was the same for all SPION sizes. 
 
 
 Because the reaction involved the polymer coating converting from carboxyl 
groups to amine groups—and hence from a negative charge to a positive charge—
reaction progress could be monitored by zeta potential. The reaction was performed 
iteratively until the zeta plateaued, indicating saturation of the nanoparticle surface 
with DPTA (Figure 6.3). Particles all seemed to saturate at a zeta potential that was 
about the same in magnitude but opposite in sign from their original zetas. For 
instance 40nm particles had a charge of -20.2 pre-reaction and saturated at a zeta of 
around +20mV. Particle sizes were also assayed by dynamic light scattering (DLS). 
Results showed that particle sizes did not change significantly with reaction, 
indicating particle stability (Figure 6.4). Sizes did seem to decrease slightly after 
reaction, possibly due to unreacted carboxyl groups buried in the polymer layer 
























Figure 6.3: Zeta potential measurements to evaluate extent of amine reaction onto 









































 With the particle size panel prepared and reacted with DPTA, we next 
investigated their DNA binding characteristics. One advantage of using cationic 
amines as a nanoparticle coating is the ability to electrostatically bind to DNA, which 
is anionic due to its phosphate groups. The number of DNA molecules each 
nanoparticle can bind is important to determine the appropriate DNA-SPION ratio to 
use for oligonucleotide transfection. To do this, nanoparticles were incubated with a 
fluorescein-labeled 21-mer single stranded DNA at different ratios. This DNA was 
identical to the oligonucleotide to be used for transfection except it contained no 
LNA-modified nucleotides. After incubation, the mixtures of SPION-fluorescently-
labeled DNA (FDNA) were loaded onto an agarose gel and electrophoresis was 
performed. Results for the four nanoparticle sizes are shown in Figure 6.5. 
 The first lane in all gels contained only fluorescein-labeled DNA. As expected, 
the DNA migrated down the gel towards the cathode due to its negatively charged 
phosphate groups. The remaining bands contained identical amounts of DNA but 
had increasing amounts of nanoparticles to match the labeled ratios. For the 40 nm 
particles, the DNA band is quite strong at a 500:1 DNA:IO ratio, indicating that most 
of the DNA remained unbound. As the amount of IO is increased, the DNA band 
begins to fade until at a 50:1 ratio, all of the DNA appears to be bound. 80 nm 
particles bound 50 DNA/particle, 150 nm particles bound 200 DNA/particle, and 200 
nm particles bound 5000 DNA/particle. Interestingly, the 40 nm and 80 nm particles 
bound similar amounts of DNA. It is unclear why this was the case but may be due to 
the two samples having similar core sizes. The DNA-SPION ratios determined by 
this experiment will be used for antagomir transfection. 
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Figure 6.5: Gel electrophoresis assays showing oligonucleotide loading onto 
amine-coated SPIONs. Ratios indicate DNA:SPION ratios. Ratios boxed in red indicate 





 With the DNA binding capacity determined for each particle size, we used the 
nanoparticles for transfecting PC-3 cells with an antagomir against miR-222, an 
oncogenic microRNA. Particle-antagomir complexes were incubated with cells at a 
40 nM antagomir concentration and SPION concentrations to achieve the 
appropriate DNA-SPION ratios as determined by the DNA binding experiments. 
Transfection was assayed by real-time PCR 24 hours post-transfection; the results 
are shown in Figure 6.6. 40 nm particles had the highest antagonism, with miR-222 
expression 51% of the no transfection control (NTC). 80nm particles had the next 
best gene antagonism, with miR-222 expression 72% of the control. Transfection 
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using 150 nm and 200 nm particles did not seem to have a statistically significant 
effect on miR-222 expression. The expression differences between the 40 nm and 




Figure 6.6: Real-time PCR data showing mir-222 expression for cells after 
antagomir transfection with different size SPIONs. Data shows comparative cT 
values, with RNU6B as endogenous control, normalized to NTC. NTC = no transfection 












































 To further explore how the SPIONs enable transfection, particle-DNA 
complexes were again incubated with PC-3 cells. Twenty-four hours post-
transfection, cells were fixed and imaged by TEM (Figure 6.7). The data shows that 
all particles tested entered into cells and localized inside endosomes. Relatively 
large numbers of particles seemed to be internalized for both the 40 nm and 80 nm 
sizes, with some endosomes containing several dozen particles. While the 150 nm 
and 200 nm particles were also internalized, relatively fewer were inside each 
endosome, with many containing fewer than 10. This is in agreement with past 
studies showing that particles larger than 100 nm exhibit decreased cellular 
internalization. Indeed, Figure 6.7 shows that several 200 nm particles were not 
internalized and remained bound to the cell membrane. This was not observed for 
the 40 nm and 80 nm particles.   
 Particles also appeared to cause rupture of endosomes, possibly through the 
proton sponge effect. This occurs when proton buffering groups, such as amines, 
are internalized by cells into intracellular compartments such as endosomes or 
lysosomes. The pH normally decreases in these compartments but amine groups 
such as those on our SPIONs can be protonated to buffer the acidic environment. 
This causes cells to pump additional H+ to acidify the endosomal compartment. This, 
however, is accompanied by endosomal Cl- accumulation, which causes osmotic 
swelling and/or lysis of the endosome or lysosome [27-29]. Rupture of endosomal 
compartments containing nanoparticles is apparent in Figure 6.7, particularly for the 
40 nm and 80 nm particles. Late endosomes are typically uniformly dark-colored by 
TEM using the staining procedures used for this experiment. The endosomes 
containing 40 nm and 80 nm particles, however, have some light-colored areas on 
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the interior of the endosomes and endosomal membranes appear to have some 
breakage. Light-colored regions are particularly apparent in images for the 80nm 
SPIONs and suggest areas where the endosomal contents were leaked into the 
cytosol.  Interestingly, it was not clear whether any nanoparticles themselves entered 
the cytosol. This would suggest that antagomirs may detach from SPIONs inside 
lysosomes and migrate themselves into the cytosol where they may antagonize miR-
222. TEM images also showed some endosomal rupture for the 150 nm and 200 nm 
SPIONs although some endosomes also appeared intact (e.g. zoomed-in TEM 
image of 150 nm particles).  Overall, the TEM studies show that amine-coated 
SPIONs, particularly with 40 nm and 80 nm diameters, enter cells and disrupt 
endosomes, supporting the transfection results. Endosomal disruption is less clear 
for the larger particles but fewer particles seem to be internalized. 
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Figure 6.7: TEM images of PC-3 cells after SPION delivery of antagomir. Images on 
right are enlarged sections of images on the left, as indicated by the box. 
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 While TEM images allowed us to track the SPIONs, we also wanted to track 
the fate of antagomirs inside the cell. We thus used TYE665-labeled LNA 
antagomirs and delivered them with our panel of SPIONs of different sizes into 
PC-3 cells.  
 First, however, we investigated the spectral properties of our labeled 
antagomirs, nanoparticles, as well as their complex. TYE665 has similar spectral 
properties as Cy5, with a maximum absorption at 557nm and a maximum emission 
at 563nm. SPIONs, however, have a relatively broad and high absorption across the 
visible spectrum (Figure 6.8). It was thus possible that upon electrostatic association 
of the particles with TYE665-labeled antagomir that the SPIONs would quench TYE 
fluorescence. To test whether fluorescence quenching occurs upon complex 
formation, we incubated TYE665-labeled antagomirs with SPIONs at molar ratios 
matching those used for cellular transfection. Emission spectra was measured for 
either fluorescently labeled antagomir (FLNA) alone or for fluorescently-labeled 
antagomirs incubated with SPIONs. Figure 6.9 shows that for all sizes tested, 
fluorescence quenching was observed. Integrated TYE665 intensities showed that 
40 nm, 80 nm, and 150 nm particles all decreased fluorescence by about 95%. 200 
nm particles lowered fluorescence by a smaller amount, about 80%, possibly due to 
























































































Figure 6.9: Emission of free FLNA and FLNA complexed with 100% DPTA SPION 
of different sizes. 
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 The observance of fluorescence quenching upon FLNA-SPION complex 
formation suggests that TYE665 signal will not be observed as long as the 
antagomirs remain associated with their nanoparticle carriers. Signal should only be 
observed once antagomirs are unloaded. We thus prepared TYE665-antagomir-
SPION complexes and used them to transfect PC-3 cells again. Cells were fixed 
both 4 hours and 24 hours post transfection and imaged. Figure 6.10 shows 
composite images containing both the DAPI and TYE665 channels. At 4 hours, no 
TYE665 signal was observed for any of the nanoparticle sizes. At 24 hours, 
however, a faint signal was observed for both the 40nm and 80nm particle sizes. 
This is in agreement with transfection data indicating that both 40nm and 80nm 
particles were able to effectively deliver antagomirs into cells to decrease miR-222 
expression. The 150 nm and 200 nm particles were not able to result in miR-222 
antagonism. Similarly, free antagomirs were not detected inside cells by 
fluorescence imaging. Overall, the data agrees with transfection data indicating that 
40 nm and 80 nm particles are able to transfect antagomirs into cells and suggests 





Figure 6.10: Fluorescence imaging showing DAPI (blue) and FLNA (red) channels 
for PC-3 cells transfected with FLNA-SPION complexes. Note that faint red signal 
can be observed in the 40 nm and 80 nm images at 24 hours. 
 
 
 In conclusion, we have investigated the effect of nanoparticle size on 
antagomir transfection into cells. Our results indicate that smaller particles may 
achieve greater miR-222 antagonism: both 40 nm and 80 nm SPIONs were able to 
achieve a statistically significant decrease in miR-222 expression with 40 nm 
particles performing better than 80 nm particles. Larger particles such as our 150 nm 
and 200 nm particles were not able to achieve a detectable knockdown in miR-222 
at all. The underlying explanation for this observed difference is yet unknown but 
may have to do with differences in ability to be internalized by cells, to rupture 
intracellular lysosomal compartments, and perhaps to even leave these 
compartments themselves. For instance, our data suggests that larger particles such 
as the 200 nm SPIONs may not be able to enter cells as efficienty as smaller 
particles such as the 40 nm and 80 nm SPION. Several 200 nm SPIONs were 
detected to remain bound to the cell membrane by TEM as long as 24 hours post-
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transfection. This was not observed for the smaller particles with the exception of 
some small-particle aggregates. Fluorescence data for TYE665-tagged antagomirs 
confirmed transfection data, with only 40 nm and 80 nm particles exhibiting signal 
indicating that antagomirs had detached from their nanoparticle carriers. While 
debate still exists on optimal nanoparticle sizes for cellular internalization, our study 
examines overall gene antagonism, for which factors such cellular internalization as 
well as breaching intracellular barriers and releasing drug cargo are all involved. For 
this purpose, our study suggests that smaller particles are superior.  
 Of course, the smallest size investigated in this chapter was 40 nm. It may 
therefore be worthwhile to study the efficiencies of particles even smaller than this to 
see if maximum gene knockdown occurs at a specific nanoparticle size or if gene 
knockdown always improves with decreasing size.  
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SUMMARY AND FUTURE DIRECTIONS 
 
7.1 Summary 
 In this dissertation, we have described methods for utilizing nanotechnology 
for cancer diagnostic and therapeutic applications. In Chapter 1 we gave an 
overview of cancer as a genetic disease with enormous complexity. This genetic 
nature calls for improved methods for the analysis of nucleic acids and delivery of 
nucleic acid drugs. We proposed nanotechnology as a tool that provides tremendous 
opportunity for addressing this need for both its ability to interact with biological 
systems at the molecular level as well as for the unique properties exhibited by 
materials at this length scale. 
 In Chapter 2, we continued discussing nanotechnology in more detail, giving 
some background on both quantum dots as well as iron oxide nanoparticles. We 
also gave background on the specific applications to be explored in the subsequent 
chapters, namely nucleic acid detection and oligonucleotide delivery. 
Chapter 3 presented a method to semi-quantitatively detect a cancer-
associated DNA sequence in solution using a sandwich assay involving quantum 
dots bound onto single magnetic microbeads. We were able to demonstrate 
sensitivity down to femtomolar values.  
 In Chapter 4, we showed that we could prepare different amine-coated 
SPIONs using EDC reaction. We showed that we could conjugate amine molecules 
onto carboxyl-coated SPIONs and monitored reaction progress by measuring zeta 
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potential. Conjugated particles were stable and discrete, demonstrated by their 
hydrodynamic diameters being unchanged from their preconjugated forms. Further, 
they remained stable even after addition of negatively-charged oligonucleotides. Gel 
binding studies indicated that all particles had oligonucleotide binding capacities of at 
least 50 DNA/SPION. 
 In Chapter 5, we demonstrated the efficacy of amine-coated iron oxide 
nanoparticles for the intracellular delivery of antagomirs against miR-222. From the 
panel of 12 particle coatings that were tested, we found that those containing 
imidazole were superior to those containing 3A or DPTA. In fact, it appeared that 
increasing imidazole content resulted in increasing gene knockdown, with 100% 
imidazole showing the best miR-222 antagonism, of around 75%. Imaging studies 
showed that particles were able to enter cells and become sequestered in 
endosomal compartments. They were able to rupture endosomes, presumably 
through the proton-sponge effect, but did not appear to leave the endosomes 
themselves. Instead, the antagomirs appeared to dissociate from their nanoparticle 
carriers and escape alone into the cytosol.  
 We investigated the effect of nanoparticle size on antagomir transfection into 
cells in Chapter 6. Our results indicated that smaller particles may achieve greater 
gene knockdown: both 40 nm and 80 nm SPIONs were able to achieve a statistically 
significant decrease in miR-222 expression, with 40 nm particles performing better 
than 80 nm particles. Larger particles such as our 150 nm and 200 nm particles were 
not able to achieve a detectable knockdown in miR-222 at all. TEM data suggested 
that larger particles such as the 200 nm SPIONs may not be able to enter cells 
efficienty as several of these particles remained bound to the cell membrane as long 
as 24 hours post-transfection. This was not observed for the smaller particles. 
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Fluorescence imaging experiments using FLNA confirmed transfection data, with 
only 40 nm and 80 nm particles exhibiting signal indicating that antagomirs had 
detached from their nanoparticle carriers.  
 
7.2 Future Directions 
 
Improving Sensitivity Limit of Bead-Based Nucleic Acid Detection 
 
 Our study utilizing MMBs and QDs to detect DNA in solution was able to 
achieve sensitivity down 200 fM. This is quite remarkable considering that the QD 
coatings were considerably negatively charged, as evidenced by their migration 
down the gel in electrophoresis experiments, even without incubation to DNA (lane 
‘0’ in Figure 3.2). Previous studies have shown that charged QD coatings exhibit 
significantly more nonspecific binding than uncharged QD coatings [1]. This may 
partially explain the existence of some signal even in samples where no target DNA 
was added (Figure 3.4C). 
 In the study, we used approximately 200,000 magnetic beads per detection 
assay and were able to detect DNA at 200 fM sensitivity. This translates into a 
detection sensitivity of approximately 100 target DNA per MMB. The sensitivity limit 
may therefore also be improved by using fewer MMBs per assay.  
 
Multiplexed Biomolecule Detection Using MMBs 
 
 We have demonstrated detection of only target DNA using one color of QD. 
One advantage of QDs, however, is multiplexing as they can be made in multiple 
colors and have broad absorption spectra combined with narrow emission spectra 
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[2]. Future work, therefore may investigate the use of multicolored quantum dots for 
multiplex detection of a panel of CNA markers.  
Alternatively, surface-enhanced Raman spectroscopy (SERS)-active gold 
nanoparticles can be used instead of QDs. SERS-active particles exhibit even 
greater sensitivity than QDs and have narrower spectra, enabling greater 
multiplexing potential [3, 4]. Furthermore, similar experiments have been performed 
to detect proteins using MMBs and QDs [5]. Multplexing studies could thus be 
performed to examine the use of this assay for the simultaneous detection of both 
DNA and protein biomarkers.  
 
SPION Delivery of Nucleic Acids 
 
 While we have identified imidazole as a superior amine molecule for delivery 
of oligonucleotides, studies need to be performed to investigate further the 
differences in performance between imidazole and non-imidazole containing 
particles as the exact reason for this observed performance difference is yet unclear. 
It may be due to the chemical properties of imidazole, with its relatively lower pKa 
and thus improved proton buffering ability and lower cationic charge at neutral pH. 
These properties may render imidazole an enhanced ability to rupture endosomes 
through the proton sponge effect or to release antagomirs into the cell relative to its 
higher pKa counterparts. 
 Studies may also explore the use of other amine molecules with other pKa 
values for oligonucleotide delivery. The current study demonstrated that imidazole 
was superior to tertiary amines and DPTA; however this does not mean that 
imidazole is the optimal amine molecule. Other amine molecules can be synthesized 
to represent other pKas, both lower and slightly higher than that of imidazole. 
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Particles coated with 100% of each of these amines could be tested and evaluated 
for gene knockdown efficiency. 
 We also demonstrated in this dissertation that smaller particles perform better 
than larger particles for oligonucleotide transfection. The smallest particle used, 
however, was 40 nm in hydrodynamic diameter. It would thus be interesting to test 
particles even smaller than this to evaluate their transfection efficiencies. In 
Appendix A, we describe the use of quantum dots of approximately 25 nm in 
hydrodynamic size. These particles exhibited antagonism of around 90%, which is 
superior to the 40 nm SPIONs. This difference, however, may not be attributed to 
size alone as the particles also had different starting surface chemistries (i.e. 
polyglucuronic acid coating for SPIONs and polymaleic anhydride coating for QDs). 
 
In Vivo Delivery 
 
 The ultimate goal of oligonucleotide delivery is to enable clinical application of 
these promising new drugs. The in vivo biological environment, however, is much 
more complex than the in vitro one that was studied here. Successful in vivo delivery 
will have to address many complex issues such as blood-nanoparticle interactions, 
immune response, biodistribution, pharmacokinetics, and toxicity. While SPIONs are 
currently approved for use in the clinic, the use of a different polymer coating 
(polyglucuronic acid coating versus polydextran for FDA-approved SPIONs) may 
imply different biological behavior and will thus need to be studied. 
 Lastly, other useful properties of iron oxide nanoparticles such as their ability 
to be used for therapy by hyperthermia or for imaging by MRI were discussed in 
Chapter 2 of this dissertation but did not fall within the scope of this study. The 
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potential for multifunctionality by these drug delivery vehicles is a major advantage 
and should be explored in future work. 
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ANTAGOMIR DELIVERY AND REAL-TIME OPTICAL IMAGING 
USING AMINE-COATED QUANTUM DOTS 
 
A.1 Introduction 
 We have included this appendix to give further data on intracellular antagomir 
delivery by nanoparticles, this time with quantum dots. The QDs are coated with an 
amine polymer that enables both antagomir binding and intracellular release. The 
QD core enables real-time tracking of delivery and allows optical visualization in live 
cells. Real-time PCR indicated miRNA knockdown of nearly 90%.  
 
A.2 Methods 
Materials    
 Agarose, octadecene (ODE; 90%), octadecylamine (ODA), poly(maleic 
anhydride-alt-1-octadecene) (Mn 7300 Da), N,N-dimethyldipropylenetriamine 
(DPTA), 4-(dimethylamino)pyridine (DMAP), and fluorescein-labeled oligonucleotide 
were purchased from Sigma. LNA-modified oligonucleotides were purchased from 
Integrated DNA Technologies (Coralville, IA).   
 
Quantum Dot Synthesis    
 
 Cadmium selenide QDs of diameter 4.5 nm were synthesized in a 
coordinating solvent following previously published procedures [1]. After purification 
via precipitation from methanol, the QDs were resuspended in a mixture of ODE and 
ODA, and then capped with a shell of CdS (2 monolayers) and then ZnS (2 
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monolayers) at 230C under argon, using organometallic precursors [2-4]. These 
ODA-passivated QDs were stored as a crude mixture at 4C and purified using 
repeated extractions in hexane–methanol, followed by precipitation with acetone 
prior to use. 
 
Quantum Dot Water Solubilization    
 
 Poly(maleic anhydride-alt-1-octadecene) was reacted with DPTA with DMAP 
as a catalyst overnight at room temperature. The reacted polymer was precipitated 
in acetone and isolated by evaporation. Reacted polymer was mixed with QDs 
(1000:1 molar ratio) in chloroform for six hours, after which the solvent was 
evaporated under a slight vacuum. The dried film was resuspended in borate buffer, 
ultracentrifuged to remove excess polymer, and then stored at 4C in the dark.   
 
QD-Nucleic Acid Complexing    
 
 QDs encapsulated with DPTA-modified polymer were complexed with nucleic 
acids by mixing and then incubating for 1 hour at 4C.  For DNA binding studies, QDs 
were complexed with fluorescein-labeled oligonucleotide by incubating in water.  For 
cell imaging and transfection studies, QDs were complexed with LNA by incubating 
in Opti-MEM.   
 
DNA Binding Assay    
 
 QDs were complexed with dye-labeled oligonucleotide as described above.  
All samples contained 0.675 nmol of dye-labeled oligonucleotide and the QD 
concentration was varied.  The samples were added to a 0.8% agarose gel 
supplemented with 0.1% Tween-20 in 1X MOPS buffer.  Electrophoresis was 
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performed for 20 min at 105 V with the gel wells near the anode.  Gels were imaged 
with a UV macro-imaging system. 
 
Cell Imaging and Transfection    
 
 PC-3 cells (ATCC, Manassas, VA) were cultured in RPMI-1640 
supplemented with 10% fetal bovine serum at 37C and 5% CO2. 
For imaging studies, cells were plated in full medium in LabTek II chamber 
slides and grown for 24 hours to about 20% confluency. The following day, media 
was removed, the cells were rinsed once with 1X PBS and incubated with either PEI-
LNA or QD-LNA complexes in Opti-MEM at 37C.  Cells were then imaged with a 
Nikon epifluorescence microscope using 488 nm laser excitation, a long pass filter, 
and a CCD camera. 
For cell transfection, cells were plated in a 96-well format and grown for 24 
hours to 60-80% confluency. Media was then removed and the cells rinsed with 1X 
PBS.  Either PEI-LNA or QD-LNA complexes in Opti-MEM were then added and the 
cells incubated at 37C. The PEI-LNA or QD-LNA solution was removed after 4 
hours.  Cells were then rinsed again with 1X PBS and incubated in regular culture 
medium at 37C.  Short RNA was isolated twenty-four hours after LNA addition using 
the miRvana RNA Isolation Kit (Ambion, Austin, TX).  RNA purity and concentration 
were quantified on a spectrophotometer (Shimadzu UV-2401PC, Kyoto, Japan).  
Cells were transfected in triplicate. 
 RNA samples were reverse transcribed using the TaqMan MicroRNA 
Reverse Transcription Kit according to the manufacturer’s instruction (Applied 
Biosystems, Foster City, CA).  Real-time PCR was then performed using the 
Taqman MicroRNA assay (Applied Biosystems, Foster City, CA). 
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 A.3 Results and Discussion 
 
 
Nanoparticle Synthesis and Characterization 
 
 The QDs prepared for this study had a core-shell structure of CdSe/CdS/ZnS.  
These particles have been shown to be highly luminescent and have greater 
photostability than CdSe cores, CdSe/CdS core/shells, and CdSe/ZnS QDs, 
presumably due to improved lattice matching between the highly-strained CdSe core 
and ZnS shell with interim layers of CdS [2, 3, 5, 6].  These QDs were roughly 6.5 
nm in diameter, with a fluorescent emission peak at 630 nm (Figure 1), 24 nm full-
width-at-half maximum, nearly 80% quantum yield, and were passivated by 
octadecylamine [7].   
 QDs were then coated with a monolayer of an amphiphilic polymer to render 
them water-soluble.  Fifty percent of the exposed hydrophilic groups was composed 
of carboxylic acid and the other fifty percent was composed of DPTA.  Figure 1 
shows the structure of the polymer along with a transmission electron micrograph 
and dynamic light scattering (DLS) data of the polymer-coated QD.  The particles 
had a diameter of roughly 18nm by DLS.  There was a correlation between the size 
of the QDs on TEM grids and their size from DLS measurements, but this 
relationship was not quantitative, most likely due to the fact that nanoparticles and 
their surrounding polymers adopt different conformations when spread and dried as 
thin films, compared to those in aqueous solution.  This is also undoubtedly as a 
result of the fundamental difference between nanoparticle hydrodynamic size 
measured by DLS and the electron density observed in TEM.  Zeta potential 
measurements indicated the particles had a surface charge of +10 mV at around 
neutral pH.  Although half of the surface functional groups are carboxylic acids, 
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which should be negatively charged, each DPTA moiety contributes a secondary 
amine, which should be positively charged, and a tertiary amine.  The positive 
surface charge may be a result of the equilibrium of protonated and unprotonated 
groups—most but not necessarily all of the carboxylic acids may be deprotonated—
and of the proximity of the various groups to the surface—the carboxyl groups are 






Figure A.1: Reaction of QD polymer coat and characterization of coated QDs. 
 
 
Nucleic Acid Delivery 
 
 The balance of functional groups is very important for nanoparticles to 
overcome the three key challenges to the cellular delivery of nucleic acids.  First, 
nanoparticles have to bind to the nucleic acid; second, they must transport the 
nucleic acid into the cell cytoplasm; and third, they must release the nucleic acid.  
We overcame the first obstacle by rendering our particles positively charged, thus 
allowing electrostatic binding to nucleic acids through their negatively charged 
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phosphate groups.  Because we were interested in the delivery of short nucleic acids 
such as siRNA and antisense, we tested binding of our QDs to a 13-base pair strand 
of DNA.  Various ratios of QD:DNA were tested from 1:100 to 1:1 and imaged via gel 
electrophoresis (Figure 2).  As we increased the relative amount of QDs, we saw 
increased binding of the DNA until the QD surface was saturated at a 1:2 ratio.  
There was no observable enhancement of DNA binding when the ratio was 
increased to 1:1.  Interestingly, while the QDs were positively charged, they did not 
migrate toward the negative electrode but instead remained in the loading well, 
possibly due to the large size of these particles. 
 
 
Figure A.2: Gel electrophoresis assay showing oligonucleotide loading onto 





DNA 1:100 1:10 1:2 1:1 
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 We next wanted to examine the ability of QDs to enter cells.  One of the 
advantages of using a quantum dot as a core nanoparticle is the ability to track 
delivery via fluorescence.  PC-3 cells were incubated with 20nM concentration of 
QDs and images were taken at varying time points (Figure 3).  Twenty nM was 
chosen because we wanted to use the concentration that gives a 1:2 QD:LNA ratio, 
which would be half the typical LNA concentration in anti-miR experiments, 40nM.  
QDs were observed to bind to the surface of the cell at 15min post incubation.  This 
may be due to electrostatic interactions between the positive surface charge of the 
QDs and the negative charge of the cell membrane conferred by its phospholipids.  
After one hour, some of the nanoparticles appear to be localized in the interior of the 
cell but there is still strong fluorescence on the cell border.  At 3 hours, almost all of 
the nanoparticles are inside the cell and fluorescence around the cell membrane is 
no longer observed.  Fluorescence of the intracellular QDs at 3 hours are punctate in 
appearance, suggesting that they are localized in endosomes.  It is worthy to note 
that no membrane-specific ligands are attached to the QDs and hence they are 
nonspecifically endocytosed.  Nevertheless, a significant amount of QDs appear to 
be uptaken by the cells.   
 
 




15 min 1 hr 3 hr 
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 To check the final step of nucleic acid release, and to verify that our 
nanoparticles can be used for delivery of nucleic acids, we delivered an LNA 
sequence designed to knockdown miR-222 in PC-3 cells using QDs, and assayed 
knockdown of the microRNA using real-time PCR.  Figure 4 shows that we are able 
to obtain close to 90% knockdown of the miRNA target with the QDs whereas only 
60% knockdown is achieved using PEI.  Interestingly, increased knockdown is 
observed with increasing QD concentration.  This is in agreement with our gel 
electrophoresis data indicating that only at a 1:2 QD:DNA ratio is all the DNA bound 
to the QD.  Also in agreement, there is no statistically significant improvement in 


















































Our imaging studies indicated that upon cellular uptake, our QDs were 
localized in endosomes; however, our transfection experiments indicated that the 
LNA was able to enter the cytosol, where it could then interact with its miRNA 
targets.  We believe the LNA enters endosomes with the QDs but then escape into 
the cytosol via the proton sponge effect.  The tertiary amines on the DPTA-modified 
polymer coating should provide pH buffering capacity to achieve this much like the 
tertiary amines of PEI.  The balance of carboxyl and secondary amine groups then 
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